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Abstract 
This project presents a mathematical model of the biochemical pathways involved in 
remyelination during multiple sclerosis. The model examines several major factors involved in 
remyelination and their expression over a course of time. This model also highlights processes 
which are targets for pharmaceutical treatment improving remyelination. The treatments 
examined include current treatments, drugs being examined for clinical trial, and theoretical 
treatments. Construction of the model is rooted in Biochemical Systems Theory (BST), which 
has been successfully applied in the past to examine the biochemistry of neurodegenerative 
disease. The model uses MATLAB as a means of coding the biochemical pathways into a system 
of ordinary differential equations (ODEs) producing a qualitative output. Use of MATLAB 
allows for a variety of treatment states, including use of drug cocktails or delayed onset of 
treatment. 
1. Introduction 
Multiple sclerosis (MS) is a neurodegenerative disorder characterized by substantial loss of the 
myelin sheath in the central nervous system (CNS), resulting in physical symptoms of pain, 
weakness, rigidity, and muscle paralysis. The loss of the myelin sheath, and the resulting 
symptoms of MS, begin with the death of oligodendrocytes (OL), cells whose primary purpose is 
the formation and maintenance of the myelin sheath. Loss of the myelin sheath can lead to 
oxidative stress of neurons and neurodegeneration. Despite this destruction, the CNS is able to 
regenerate certain amounts of myelin due to the presence of oligodendrocyte progenitor cells 
(OPCs), which may migrate to the site of MS lesions and differentiate into myelin forming 
oligodendrocytes, alleviating certain symptoms of the disease (Podbielska et al., 2013). The 
promotion of this differentiation involves receiving signals from neurons, immune cells, and 
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other glia. Once differentiated, cells will produce the components of myelin, including lipids and 
myelin proteins. This paper presents a mathematical model detailing the impact of signals 
received by OPCs and the downstream effect these signals have on transcription and translation 
of differentiation markers, as well as the resulting transcription and translation of myelin 
proteins.     
Research into the causes of MS has led to multiple hypotheses about its origin, with emphasis on 
the roles of inflammation and the immune response as primary sources of demyelination. 
Multiple sclerosis is therefore the most common autoimmune disorder affecting the CNS 
(Stadelmann, 2011). Patients with MS frequently present a relapsing-remitting course, in which 
subsequent immune and inflammatory attacks can cause further severe symptoms (Compston & 
Coles, 2002). Most pharmaceutical treatments focus on reducing the severity or frequency of 
immune system attack. Of these, the most well-known are the β-interferons (Podbielska et al., 
2013). However, these treatments do not fully resist the disease and its symptoms, and research 
has shifted to searching for pharmaceutical targets which may promote remyelination (Kremer, 
Küry, & Dutta, 2015). 
The model presented here utilizes Biochemical Systems Theory (BST), a mathematical modeling 
framework established by Savageu in 1969. BST has been utilized successfully to analyze a 
variety of neurodegenerative diseases including multiple sclerosis (Broome & Coleman, 2011; 
Braatz & Coleman, 2015). Ordinary differential equations (ODE) are used to model 
concentrations of species and reaction rates, in order to represent the progression of multiple 
sclerosis over time. The baseline model includes a healthy state and a disease state, and 
compares the success of remyelination in both states. The healthy state represents a system in 
which no demyelination takes place, while the disease state examines remyelination in the 
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presence of inflammatory demyelinating signals. The disease state is created by adding a trigger 
point, in this case demyelination, or by modifying concentrations of certain species to reflect 
evidence found in current research. In addition, various treatment states are presented. The 
treatment states mimic the mechanism of action of a known or theoretical treatment for MS, and 
are utilized both beginning at the onset of the disease and partway through progression, 
representing a delay in treatment during diagnosis. The treatments examined target key reactions 
in the pathology of MS, and aim to provide insight into their potential success outside of a BST 
model. 
2. Methods 
2.1 Pathways of OPC Differentiation 
This section describes major pathways and contributing signals involved in the differentiation of 
oligodendrocyte progenitors into myelin generating oligodendrocytes. These pathways were 
represented visually using the program CellDesigner. In the accompanying models, arrows 
indicate transitions between species. Formation of complexes was considered reversible unless 
otherwise indicated. Modulation of reactions is represented with an open circle for catalysis and 
a hard edge for inhibition. A full version of the model may be found in the Appendix. 
2.1.1 Important Markers of OPC Differentiation 
This section focuses on a variety of contributors to differentiation of oligodendrocyte progenitors 
and the overall promotion of that differentiation. However, differentiation is not a step-by-step 
process, but a gradual transition that can be generally marked by increased expression of certain 
proteins. Among the most important of these are: oligodendrocyte transcription factor 2 (Olig2), 
Homeobox protein Nkx2.2, platelet derived growth factor receptor alpha (PDGFRα), neural/glial 
antigen 2 (NG2), oligodendrocyte marker 1 (O1), and oligodendrocyte marker 4 (O4) (Hu, Du, & 
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Zhang, 2009). These markers not only act as useful tools for researchers, but some play active 
roles in the processes outlined below. 
2.1.2 Neuronal Contribution 
The destruction of the myelin sheath reveals several proteins and receptors expressed by neurons 
that are not previously active or involved in signaling. These proteins may bind to receptors on 
other cells, most notably on OPCs, as shown in Model 1. Laminin proteins are expressed by the 
neuron, and upon removal of the myelin sheath may bind to different receptors. Laminins bind 
the Integrin alpha-V (ITGAV) receptor and activates p38 mitogen-activated protein kinase (p38 
MAPK) signaling, promoting OPC differentiation (Podbielska et al, 2013; Zhao et al., 2009). 
Laminins may also bind the dystroglycan receptor, activating p38 MAPK signaling (Galvin, 
Eyermann, & Colognato, 2010). L1 cell adhesion molecule (L1) from the neuron binds to 
Contactin 2 on the OPC and activate the selective phosphorylation of Fyn kinase, promoting 
differentiation (Podbielska et al., 2013). Contactin 1 of the neuron will also be revealed and 
activate a Notch signaling pathway which activates deltex 1 in the OPC, encouraging 
differentiation (Podbielska et al., 2013). Neurodegeneration will also lead to a release of 
purinergic signals from neurons. Adenosine has been shown to activate OPC differentiation, 
while uridine diphosphate (UDP), acting at the cysteinyl leukotriene receptor (GPR17), inhibits 
adenylate cyclase causing downstream inhibition of differentiation (Fumagalli, Lecca, & 
Abbracchio, 2016). 
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Model 1: Signals from demyelinated neurons affecting OPC differentiation 
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2.1.3 Astrocytic Contribution 
Another chief source of intercellular signals related to OPC differentiation comes from a second 
type of glial cell, astrocytes. Model 2 shows all major products of astrocytes important in this 
differentiation. The first product, endothelin 1 (ET-1) shows increased expression in astrocytes 
following demyelination and in turn stimulates astrocytic expression of Jagged1 (Hammond et 
al., 2014). Jagged1 activates a Notch signaling pathway in the OPC which inhibits 
differentiation, but promotes OPC migration to the site of lesion (Brosnan & John, 2009).  
A second signal produced by the astrocyte which activates signals for OPCs is ciliary 
neurotrophic factor (CNTF). Interleukin-1 beta (IL-1β), which is present in lesions following 
demyelination, is found to increase astrocytic expression of CNTF, and CNTF in turn promotes 
astrocytic expression of fibroblast growth factor 2 (FGF-2) as well as expression of fibroblast 
growth factor receptor 1 (FGFR1) by the OPC (Moore et al., 2011; Albrecht et al., 2003). 
Directly on the OPC, CNTF activates glycoprotein 130 receptor tyrosine kinase (gp130), 
promoting Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) 
signaling and OPC differentiation (Steelman et al., 2016). FGF-2 has been shown to inhibit OPC 
differentiation upon binding FGFR1 on the OPC (Murtie et al., 2005).  
A third signal, Tenascin C (TnC), is expressed by the astrocyte and acts on the OPC. TnC 
binds to ITGAV, activating p38 MAPK signaling (Zhao et al., 2009). Another signal, platelet 
derived growth factor (PDGF) is expressed to module OPC differentiation. Acting as a receptor 
tyrosine kinase, the PDGFRα expressed by the OPC inhibits differentiation by promoting the cell 
proliferation pathways, while also encouraging differentiation through the activation of protein 
kinase B (Akt) pathways (Murtie et al., 2005; McKinnon, Waldrin, & Kiel, 2005). The presence 
of tumor necrosis factor alpha (TNFα) in lesions following demyelination activates nuclear 
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factor kappa-light-chain-enhancer of activated B cells (NF-κB) in the astrocyte, which promotes 
the expression of two more signaling molecules: CXCL12 and LIF (Patel et al., 2012; Fischer et 
al., 2014.) C-X-C motif chemokine 12 (CXCL12) inhibits differentiation upon binding the C-X-
C motif chemokine receptor 4 (CXCR4) receptor on the OPC (Patel et al., 2012). Leukemia 
inhibitory factor (LIF), similar to CNTF, binds gp130 and promotes JAK/STAT signaling 
leading to differentiation (Steelman et al., 2016).  
2.1.4 Immune Contribution 
Model 3 outlines signals received by the OPC from a T helper 2 cell. The role of the immune 
system in MS has become increasingly more clear, and these signals demonstrate the immune 
system’s minor role in remyelination. PDGF is released from these Th2 helpers and is able to act 
on the OPC through the same mechanism as when released by an astrocyte (Skihar et al., 2009). 
Brain derived neurotrophic factor (BDNF) is released and acts on the OPC at the tropomyosin 
receptor kinase B (TrkB) to promote differentiation by activating Fyn kinase and Akt (Skihar et 
al., 2009; Peckham et al., 2016). Insulin-like growth factor 1 (IGF-1) released by the Th2 helper 
cell binds the insulin-like growth factor receptor 1 (IGFR1) on the OPC to activate the p38 
MAPK pathway and activate phosphoinositide 3-kinase (PI3K), which further activates Akt 
(Mason et al., 2003).  
2.1.5 LINGO-1 Receptor Activation 
An important neuronal contributor worthy of mentioning independent of other signals is the 
leucine rich repeat and immunoglobin-like domain-containing protein 1 (LINGO-1) (Model 4). 
Like other neuronal signals, it is able to interact with the OPC upon significant demyelination. 
LINGO-1 has been shown to inhibit axonal regeneration in multiple CNS disorders (Podbielska 
et al., 2013). In MS, it has been repeatedly shown to inhibit OPC differentiation, and is a major 
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target for potential pharmaceutical treatment (Jepson et al., 2012; Mi, Pepinsky, & Cadavid, 
2013). LINGO-1 binds to the receptor tyrosine-protein kinase erbB-2 (Erb2) on the OPC and 
exerts two main effects. The first is an inhibition of the binding of BDNF to TrkB (Mi, Pepinsky, 
& Cadavid, 2013). The second is an activation of Ras homolog gene family member A (RhoA) 
signaling, which has been shown to interact with Rho-associated protein kinase (ROCK) and 
inhibit p38 MAPK signals, as well as stop inhibit the transcription of phosphatase and tensin 
homolog (PTEN) (Baer et al., 2009; Paintlia et al., 2010; Jepson et al., 2012). The formation of 
this complex is stimulated by geranylgeranyl pyrophosphate (Paintlia et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 2: Astrocytic signals effecting OPC differentiation 
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Model 3: Th2 Helper cell signals effecting OPC differentiation 
 
2.1.6 Role of Muscarinic Acetylcholine Receptors 
Neurodegeneration may lead to release of neurotransmitter in the site of lesions. For this reason, 
muscarinic acetylcholine receptors expressed by OPCs play a major role in the differentiation of 
OPCs, as well as in remyelination itself. Model 5 shows the processes effected by the binding of 
acetylcholine to different muscarinic receptor subtypes. Expression of PDFRα and Notch1 is 
increased by binding at the M3 and M4 receptors (De Angelis et al., 2011). Transcription of 
myelin basic protein (MBP), a major component of the myelin sheath, is upregulated by binding 
at the M1 and M3 subtypes (De Angelis et al., 2011). Formation of cyclic adenosine 
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monophosphate (cAMP) is upregulated by binding at the M1 subtype through activation of 
adenylate cyclase, but inhibited by binding at the M2 and M4 receptors (De Angelis et al., 2011). 
 
Model 4: LINGO-1 Signaling on the OPC 
 
cAMP activates protein kinase A (PKA) which phosphorylates extracellular signal-regulated 
kinases (ERK) to encourage differentiation (Medina-Rodriguez et al., 2013). Binding of 
acetylcholine at the M1 and M4 receptors inhibits expression of receptor tyrosine-protein kinase 
erbB-3 (ErB3) and receptor tyrosine-protein kinase erbB-4 (ErB4) which activate PI3K in the 
presence of neuregulin 1 (NRG1) type III, a growth factor (De Angelis et al., 2011; Taveggia et 
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al., 2008). Model 6 demonstrates the downstream effects of the relevant receptors and signals 
regulated by the muscarinic acetylcholine receptors. 
 
Model 5: Signals modulated by muscarinic acetylcholine receptors 
2.1.7 Role of Vitamin A 
Evidence points to the role of several vitamins, primarily vitamin D, in the biochemistry of MS 
(Ascherio, Munger, & Simon, 2010). Another vitamin, vitamin A, plays a small role in 
remyelination. Vitamin A’s derived metabolite, 9-cis-retinoic acid (9cRA), is an agonist of the 
retinoid X receptor gamma (RXRγ). Activation of RXRγ has been shown to lead to an increase 
in OPC differentiation (Huang et al., 2010). This pathway, outlined in Model 7, is of 
pharmaceutical interest, as the activation of the smoothened receptor (SMO) on the OPC leads to 
upregulation of RXRγ (Porcu et al., 2015).   
12 
 
 
Model 6: Downstream effects of signals regulated by muscarinic acetylcholine receptors 
 
2.1.8 Major Cell Signaling Pathways and Transcription Factors Activated 
The next section outlines the common intracellular signaling pathways as they directly impact 
OPC differentiation. The end result of these pathways is the activation of major transcription 
factors directly involved in proteins responsible for the differentiation of OPCs. These pathways 
are activated or inhibited by multiple signals impacting the OPC as described in the above 
sections. 
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Model 7: Vitamin A metabolite in OPC Differentiation 
 
2.1.8.1 Wnt Signaling Pathway 
Protein Wnt-3a (Wnt-3a), found in MS lesions, begins an important intracellular signaling 
pathway in the OPC by binding to low-density lipoprotein related receptor proteins (LRP) 5 and 
6, members of the Frizzled family of receptors, to inactivate glycogen synthase kinase 3 beta 
(GSK3β) (Preisner et al, 2015; Xie et al., 2014) (Model 8). The active form of GSK3β helps 
degrade β-catenin, a protein which inhibits the production of several important transcription 
factors, including zinc finger E-box-binding homeobox 2 (SIP1), myelin regulatory factor 
(MYRF), and yin-yang 1 (YY1), all of which are involved in OPC differentiation (Zhou et al., 
2014). However, β-catenin also works with transcription factor 4 (Tcf4) through an unknown 
mechanism to encourage OPC differentiation (Xie et al., 2014). 
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Model 8: Wnt signaling pathway in OPC 
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2.1.8.2 JAK/STAT Signaling 
The specific actions of JAK/STAT pathways in a differentiating OPC are outlined in Model 9. 
As outlined above, LIF and CNTF bind the gp130 receptor. This binding activates JAK2, which 
phosphorylates the gp130 receptor, leading to phosphorylation of STAT3, a key transcription 
factor involved in differentiation (Steelman et al., 2016). Another STAT pathway is activated by 
the presence of an interleukin found in MS lesions, IL-6. IL-6 binds to the soluble interleukin 6 
receptor (sIL-6R) to form a chimeric protein which leads to phosphorylation and activation of 
STAT1, another transcription factor involved in OPC differentiation (Valerio et al., 2002). 
 
Model 9: Activation of STAT transcription factors 
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2.1.8.3 Akt/mTOR Pathway 
The molecular target of rapamycin (mTOR) is another vital transcription factor involved in the 
differentiation of OPCs and is activated through a phosphorylation cascade (Inoki et al., 2006) 
(Model 10). Activation of PI3K, inhibited by PTEN, leads to activation of 3-phosphoinositide 
dependent protein kinase-1 (PDK1) (McKinnon et al., 2005; Paintlia et al., 2010). PDK1 
phosphorylates Akt, which subsequently phosphorylates mTOR to activate it (Lin et al., 2013; 
Luo et al., 2014). mTOR is also involved in activating the ribosomal protein s6 kinase beta-1 
(S6K), which promotes the synthesis of myelin proteins (Michel et al., 2015). 
 
Model 10: Akt/mTOR signaling in the OPC 
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2.1.8.4 ERK, MAPK, and CREB 
Phosphorylation of the cAMP response element-binding protein (CREB), an important 
transcription factor, is a key event in the differentiation of OPCs (Syed et al., 2013) (Model 11). 
Three sources of phosphorylation are modeled for CREB in OPC differentiation. The first is the 
phosphorylation of p38 MAPK by signals mentioned above, including activated PKA, as well as 
sphingosine-1-phosphate (S1P) signaling (Cui, Fang, Kennedy, Almazan, & Antel, 2014). This 
phosphorylated p38 MAPK then phosphorylates MAP kinase-interacting serine/threonine-
protein kinase (MNK), which phosphorylates CREB (Syed et al., 2013). The second signal is 
phosphorylation by activated Akt (Meffre et al., 2015). The third is activation by phosphorylated 
ERKs (Rodgers et al., 2015).  
Model 11: Phosphorylation of CREB by multiple pathways 
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2.2 Apoptotic signals effecting OPCs 
One reason remyelination in multiple sclerosis may fail is due to the death of OPCs. Model 12 
outlines apoptotic signals received by the OPC. TNFα, one of the main inflammatory signals 
found in MS, binds to death receptor 6 (DR6) on the OPC activating a caspase chain in which 
procaspase 8 is converted to caspase 8, which converts procaspase 3 to caspase 3 leading to 
apoptosis. This pathway is inhibited by the tyrosine-protein kinase Lyn (Mi et al., 2011). A 
second pathway, also inhibited by Lyn, but stimulated by apoptosis regulator Bax (Bax), is the 
release of cytochrome c (CytC) from the mitochondria into the cytoplasm. This release activates 
conversion of procaspase 9 to caspase 9, which may be phosphorylated and lead to apoptosis 
(Pang et al.,2007). Apoptosis is also directly stimulated by Bcl-2-associated death promoter 
(BAD). BAD is inhibited in this action by phosphorylation by Akt, or in binding to B-cell 
lymphoma 2 (Bcl-2) (Pang et al., 2007). Bcl-2 expression is increased by phosphorylated STAT3 
(Steelman et al., 2016). 
2.3 OPC Proliferation 
An important part of remyelination not yet discussed is the proliferation of OPCs, or the 
expansion of the number of OPCs. In order for remyelination to be sustained, the pool of OPCs 
must remain active, especially if there is still potential for further attack by the immune system. 
However, OPC proliferation means continuation of the cell cycle by the OPC, preventing 
differentiation (Redwine et al., 1998; Murtie et al., 2004). For this reason, OPC proliferation may 
encourage remyelination over the long term, but inhibits remyelination in the short term. 
Because of the unclear extent to which OPC proliferation plays this dual role, it was considered 
primarily as an inhibitor of OPC differentiation. The signals involved in modulating OPC 
proliferation are shown in Model 13. Two signals, PDGF and CXCL12 have been described 
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previously as astrocytic factors which encourage proliferation (Murtie et al., 2004; Patel et al., 
2012). OPC Proliferation is also stimulated by Lyn kinase (Watzlawik et al., 2010). The 
transcription factor sex determining region Y-box 2 (SOX2) acts to simulate OPC proliferation 
through an unknown mechanism (Zhao et al., 2015). Demyelinated lesions also increase the 
presence of transforming growth factor alpha (TGFα) and heparin-binding epidermal growth 
factor (HB-EGF) which both bind and activate the epidermal growth factor receptor (EGFR) to 
encourage proliferation (Aguirre et al., 2007). Proliferation has also been shown to be inhibited 
by the binding of adenosine to P1 type receptors (Fumagalli, Lecca, & Abbracchio, 2016). 
Model 12: Apoptosis inducing factors effecting the OPC 
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Model 13: Factors encouraging OPC proliferation 
2.4 OPC Migration  
In addition to successful differentiation, OPCs must also be recruited to the site of the lesion for 
successful remyelination, in a process termed here as OPC migration. OPC migration is 
encouraged through multiple signals (Model 14). Binding of laminins will encourage the 
activation and complex formation of integrin-linked kinase (ILK) to members of the Parvin 
protein family, which play a role in binding actin (O’ Meara et al., 2016). Fyn kinase may 
activate cyclin-dependent kinase 5 (Cdk5), leading to the phosphorylation of Wiskott-Alrich 
syndrome protein family member 2 (WAVE2), an important transcription factor for proteins 
binding actin (Miyamoto, Yamauchi, & Tanoue, 2008). Binding of glutamate, which may be 
present in the site of neurodegenerative lesions, to the N-methyl-D-aspartic acid (NMDA) 
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receptor leads to phosphorylation of T lymphoma invasion and metastasis 1 (Tiam1), a 
guanonucleotide exchange factor for Ras-related C3 botulinum toxin substrate 1 (Rac1), the 
activated form of which encourages OPC migration (Xiao et al., 2013). Finally, oligomers of 
hyaluronic acid (HA), binding to the CD44 antigen on OPCs has been show to activate migration 
(Piao, Wang, & Duncan, 2013). HA has been shown to be prevalent in demyelinated lesions, 
especially in its high molecular weight (HMW) form and can act as an inhibitor of OPC 
differentiation (Back et al., 2005). HA interacts with myeloid differentiation primary response 
protein (MyD88) and Toll-like receptor 2 (TLR2) to inhibit OPC differentiation. The majority of 
HA acting in this signaling is produced when HMW-HA is broken down by the enzyme 
hyaluronidase to smaller HA subunits (Sloane et al., 2009). 
2.5 Production of Myelin Components 
The second focus of this model examines the production of proteins of the myelin sheath. There 
has not been substantial evidence that there is metabolic dysfunction in remyelination related to 
lipid catabolism (Wheeler et al., 2008; Podbielska et al., 2013). Of vital relevance is the need to 
transcribe and translate new proteins to support and maintain the new myelin sheath. The species 
representing OPC differentiation is modeled as catalyzing the production of these myelin 
proteins. There is evidence that remyelination follows similar pathways to that of developmental 
myelination (Miller & Mi, 2007; Fancy et al., 2011). For this reason, some evidence related to 
developmental myelination has been used to support the processes outlined here for 
remyelination.  
2.5.1 MBP 
MBP is the most studied of the myelin proteins, likely due to its role as the primary antigen in 
the immune response in MS (Tzakos et al., 2005). For this reason, MBP is the protein modeled in 
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the most detail in this project. Production of MBP is divided into three major steps. The MBP 
gene is transcribed into an mRNA. Next, this mRNA is translocated to the cell membrane, where 
it is finally translated into MBP (Müller et al., 2013).  
Model 14: OPC migration signals 
 
2.5.1.1 MBP Transcription 
Transcription of the MBP gene is promoted and inhibited by numerous species (Model 15). The 
M1, M3, and M4 Ach receptors have already been noted to activate the MBP gene (Model 5). 
Homeodomain transcription factor Gtx (Gtx) and phosphorylated STAT3 have been shown to 
activate the MBP gene (Sim, Hinks, & Franklin, 2000; Steelman et al., 2016). Cyclin-dependent 
kinase inhibitor 1 (p21) and cyclin-dependent kinase inhibitor 1B (p27) have both been shown to 
encourage transcription of MBP (Paintlia et al., 2010). MYRF is a unique transcription factor 
which activates itself autoproteolitcally and then targets the MBP gene (Emery et al., 2009; 
Bujalka et al., 2013). Transferrin and IGF-1 both activate the production of MBP mRNA 
(Espinosa-Jeffrey et al., 2002). The hormone erythropoeitin increases expression by increasing 
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expression of early growth response gene 2 (Egr2) which acts on the MBP gene (Cervellini et al., 
2013). Transcription factors Olig1 and Sox10 work together to promote transcription of MBP (Li 
et al., 2007). Trans-acting transcription factor Sp5 (Sp5) acts to inhibit transcription of the gene 
(Xie, Li, & Zhang, 2014). Binding of bone morphogenic protein 4 (BMP4) released from 
neurons at its receptor (BMPR) has been shown to inhibit transcription of MBP and may inhibit 
OPC differentiation (Weng et al., 2012; Xie et al., 2014). Transcription factor Nkx2.2 has been 
shown to regulate the transcription of the MBP gene by recruiting a complex of histone 
deacetylase 1 (HDAC1) and paired amphipathic helix protein Sin3a (mSin3a), but is inhibited in 
this action by transcriptional activator protein Pur-alpha (Pur-α) (Wei, Miskimins, & Miskimins, 
2005).  
2.5.1.2 MBP mRNA Translocation 
MBP mRNA packs into granules with all the necessary components for translation and 
translocates to the site of myelination before translation occurs (Müller et al., 2013). The factors 
assisting in this process are shown in Model 16. PDGF encourages this translocation through a 
still unknown mechanism (Amur-Umarjee, Schonmann, & Campagnoni, 1997). The granules 
travel along the microtubule network, and the microtubule associated protein tau (MAPt) is vital 
to the assembly of this network (Seiberlich et al., 2015). The movement along the microtubules 
is facilitated by kinesin motor protein Kif1b (Lyons et al., 2009). Finally, heterogeneous nuclear 
ribonucleoprotein A2 (hnRNP A2) is an essential trafficking factor that assists in the formation 
of the transport granules, and binds the mRNA to prevent translation until transport is complete 
(Francone et al., 2007; Müller et al., 2013). Small non-coding RNA 715 (sncRNA 715) has also 
been shown to inhibit translation of MBP mRNA until proper translocation is complete (Bauer et 
al., 2012). 
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2.5.1.3 MBP mRNA Translation 
Translation of MBP is a highly regulated process (Model 17). Once localized to the site of 
myelination, translation is initiated by eukaryotic initiation factor 4e (eIF4e). eIF4e is inhibited 
by 4e binding protein 1 (4EBP1). The binding of neurotrophin-3 (NT-3) at the TrkC receptor 
activates p38 MAPK and Akt signaling, which leads to phosphorylation of both eIF4e and 
4EBP1, allowing the former to initiate translation (Coelho et al., 2009). Ribosomal protein s6 
(S6RP), a major protein of the ribosomal complex, is phosphorylated by S6 kinase (S6K) in 
response to ERK signaling, allowing for proper translation (Michel et al., 2015). As described 
previously, hnRNP A2 acts to repress translation until proper translocation of the mRNA, but 
this action is relieved when Fyn kinase phosphorylates hnRNP A2 (White et al., 2008). There is 
evidence that tumor overexpressed gene protein (TOG) assists in the alleviation of hnRNP A2 
repression of translation (Francone et al., 2007).  
2.5.2 PLP 
Proteolipid protein (PLP) is the most abundant protein in CNS myelin (Tzakos et al., 2005). The 
transcription and translation of PLP are shown in Model 18. Activators of PLP transcription 
include the following transcription factors: Nkx2.2, Gtx, Olig2, YY1, and MYRF (Fu et al., 
2002; Sim, Hinks, & Franklin, 2000; Berndt et al., 2001; Emery et al., 2009). In addition, 
HDAC11 relieves the inhibition of histone 3 (H3) in the area of the PLP gene (Liu et al., 2009). 
Finally, the nuclear lamin B proteins have been shown to increase transcription of PLP through 
an unknown mechanism (Lin et al., 2013). 
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Model 15: Transcription of MBP mRNA 
 
 
 
 
 
 
 
 
 
 
Model 16: Translocation of MBP mRNA 
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Model 17: Translation of MBP 
 
Model 18: Transcription and translation of proteolipid protein 
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2.5.4 Minor Myelin Components  
Though important to the integral structure of myelin, several myelin proteins are considered 
minor contributors in this model (Model 19). This consideration is primarily due to a lack of 
literature related to the production of these proteins in a remyelination context. These proteins 
included in this model include: 2’, 3’-Cyclic-nucleotide 3’phosphodiesterase (CNPase), myelin-
associated glycoprotein (MAG), myelin protein zero (MPZ), and myelin oligodendrocyte 
glycoprotein (MOG). All proteins were modeled to have their production stimulated by OPC 
differentiation. MYRF stimulates the transcription of both the MAG and MOG genes (Emery et 
al., 2009; Bujalka et al., 2013). Phosphorylated eIF4e is known to stimulate translation of the 
MAG and MOG mRNAs, while the eIF4e/4EBP1 complex inhibits translation (Coelho et al., 
2009). 
 
 
 
 
 
 
 
Model 19: Production of minor myelin contributors 
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2.5.5 Squalene synthesis 
It has been stated that production of myelin lipids has not been found to be a significant concern 
in remyelination (Wheeler et al., 2008; Podbielska et al., 2013). However, the synthesis pathway 
of squalene, the major precursor to cholesterol, has been shown to interact in OLs and precursors 
through other means. More specifically, the creation of geranylgeranyl pyrophosphate from 
farnesyl pyrophosphate has been shown to catalyze the interaction between RhoA and ROCK 
proteins (Paintlia et al., 2010) (Model 4). At the same time, as squalene is a precursor to 
cholesterol, which is a vital lipid abundant in myelin, it is modeled here as positively impacting 
remyelination (Model 20). This pathway is of particular interest as there is some evidence of 
HMG CoA reductase inhibitors having positive effects on remyelination (Paintlia et al., 2010). 
 
Model 20: Squalene synthesis pathway 
 
29 
 
2.6 Overall Factors Contributing to Remyelination 
Remyelination was itself considered as a reaction progressing demyelinated lesions to 
remyelination (Model 21). Differentiation was considered only for its role in the production of 
the various myelin components, and therefore is not represented in the modulation of this 
reaction. The reaction is show to be upregulated by the following myelin components: MBP, 
CNPase, PLP, MPZ, MOG, MAG, and squalene. Remyelination was also catalyzed by OPC 
migration. Inhibiting remyelination is apoptosis, as the death of myelin producing cells would 
prevent remyelination.  
Model 21: Factors directly considered in remyelination as a species 
2.7 Computer Modeling 
The visualized CellDesigner model was converted into a mathematical form using BST. 
MATLAB coding software was used to model species concentrations and reaction rates over 
time. For examples of applications of BST to neurodegenerative disease see this lab’s previous 
work (Broome & Coleman, 2011; Braatz & Coleman, 2015). For a full copy of the MATLAB 
code used in this model, see the Appendix. 
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2.7.1 Differential Equations 
The model constructed here is a system of nonlinear, first order, autonomous ordinary 
differential equations. The equations fall into two categories: system equations and rate 
equations. 
2.7.1.1 System Equations 
System equations are assigned to each dependent variable to describe the change in 
concentration of that species over time. The concentration of a reactant leading to a particular 
species is multiplied by a rate constant or rate equation, and these values are then summed 
together to form a species’ system equation. Likewise, if a dependent variable species leads to 
another species, then the appropriate rate constant or rate equation multiplied by that species 
concentration is subtracted in the first species’ rate equation. For example,  
dX(287) = X(102) * Xind(99) – X(118) * X(287) 
where dX(287) represents the change in concentration of X(287), MBP mRNA, Xind(99) 
represents the MBP gene, and X(102) and X(118) represent the related rate equations. The first 
part of the statement represents the transcription of the gene, and the second, the mRNA being 
translated. 
2.7.1.2 Rate Equations 
Rate equations are a way of representing modifiers to the rate of a specific reaction. If a reaction 
has no catalyzers or inhibitors, it was given a rate constant value, represented as “k”. For 
example, the production of O1 was given an equation of:  
dX(252) = k(71) * Xind(103) 
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where X(252) is O1 and Xind(103) is the O1 gene. For reactions with modifiers, rate equations 
were written. These equations consist of a constant multiplied by a sum of all species promoting 
or inhibiting the reaction, with inhibitors being viewed as negative. Model 22 is used to show an 
example of a rate equation. 
 
 
 
Model 22 – Production of cAMP 
Model 22 would be given the following associated equations: 
dX(80) = 0.01 * X(286) 
dX(259) = X(80) * Xind(111) 
The first equation is a rate equation corresponding to how quickly or slowly X(286), adenylate 
cyclase, increases the rate of the reaction, X(80). The second equation is a system equation 
demonstrating the rate of change in the concentration of X(259), cAMP, as it relates to the rate, 
X(80), and the concentration of reactant, Xind(111), ATP. 
2.7.2 Initial Values 
Each variable in the model was assigned an initial value. Variables were given one of two 
designations: independent or dependent. Independent variables are those which are not a product 
of any reaction in the model. The values were obtained in parts per million through the use of the 
proteomics database PaxDB and converted using mean values on brain size and mass. In 
addition, values were modified on a relative basis allowing for estimation of values when no data 
is available.  
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2.7.3 Baseline, Disease, and Treatment Conditions 
Data was analyzed through a baseline control state, a disease state, and various treatment 
conditions. The analysis is represented as a difference between the disease and the baseline state. 
Therefore, any species with a positive value indicates that the model predicts an increase in that 
species during MS. Likewise, any negative value implies a decreased concentration of that 
species in MS. Treatment states are compared to the baseline state in the same fashion as a 
disease state. Two types of treatment condition were examined. The first was a condition in 
which the treatment species concentration was active from the beginning of the run (t = 0). The 
second was a condition in which the treatment species concentration began at zero, but was 
initiated part way through the run (t = 75). This second method represents treatment of a disease 
after a period of time during which symptoms would appear and a diagnosis was made. 
3. Results 
Results examine various treatments for MS and their impact on remyelination. The results 
presented are a qualitative analysis of relative differences between various states. The 
representation is presented as five different scenarios: a baseline disease state, treatment from t=0 
at low dose, treatment at t=75 at low dose, treatment at t=0 at high dose, and treatment at t=75 at 
high dose. The doses examined, when compared against the values obtained for protein 
concentration data, represent concentrations of 0.01 nM for low dose and 0.1 nM for high dose. 
Each treatment is considered and results are presented with relevance to the molecular signaling 
pathways effected.  
3.1 Disease/Baseline State Overall 
The state referred to as the “disease state” or “baseline state” is a representation of the difference 
between the model run in MATLAB with MS-related initial concentrations and a healthy state 
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with no MS-related initial concentrations. The primary difference between these two runs is the 
presence of the species labeled “demyelination”. Figure 1 shows the qualitative result of the 
baseline state with regard to the species “remyelination”, which is an overall indicator of disease 
progression in the model. The model predicts three distinct phases. The first is a segment of little 
difference between a healthy and disease individual with regard to remyelination. The second 
segment shows a marked increase in remyelination compared to a healthy individual with no 
demyelination. The third and final period is a steady decline in overall remyelination over time. 
Of note is the continuing occasional spiking seen during this remyelination decline, implying 
occasional successful remyelination. These results are the baseline for which all treatments were 
examined for their overall efficacy. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Baseline remyelination predicted by MATLAB model 
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3.2 Treatments for MS 
The results that follow examine pharmaceutical treatments that are already in use or are in 
consideration for use in the treatment of MS. The treatments are separated by their respective 
mechanisms of action. 
3.2.1 Immunomodulation 
The first drug considered is Glatiramer Acetate (GA). GA is used currently in the treatment of 
relapsing-remitting MS and targets immune cells, including the activation of Th2 helper cells. 
The role of these cells was described in section 2.1.4. Evidence has shown that GA will promote 
the expression of important neurotrophic factors by the Th2 Helper cell, including PDGF, 
BDNF, and IGF-1 (Skihar et al., 2009). While GA is already a viable treatment option for 
targeting immune response in MS, this model examines its efficacy in promoting remyelination, 
exploring its potential dual role in treatment. The effect of GA on overall remyelination is 
demonstrated in Figure 2. Use of a high dose from the beginning of pathology results in a 
delayed, but overall more significant remyelination compared to all other states. All other states 
follow a relatively similar pathway of disease progression, but over time it is clear that a higher 
dose, even given part way through disease progression, results in increased remyelination 
compared to the baseline state. The low dose curves show some improvement over baseline, but 
not at the level of the higher dose. Among the factors modeled as effecting remyelination 
success, the model predicts treatment with GA significantly lowers levels of apoptosis (Figure 
3).  
3.2.2 Anticholinergics 
Other considerations for treatment have looked at the effect of neurotransmitters on 
oligodendrocyte differentiation and subsequent remyelination. Two such drugs to be recently 
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examined are Benztropine and Clemastine (Deshmukh et al., 2013; Mei et al., 2014). Both drugs 
are anticholinergic drugs, with Benztropine known to exert its action on specifically the M1 and 
M3 receptor subtypes, while Clemastine is primarily an antihistamine with anticholinergic 
properties (Deshmukh et al., 2013; Mei et al., 2014). As of May 2016, both drugs were being 
considered for clinical trial, and of particular interest as both are already approved by the Food & 
Drug Administration (Juarez, He, & Lu, 2016). The model successfully reduces the number of 
complexes between ACh and muscarinic receptors (Figure 4). The model predicts full, early  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Effect of Glatiramer Acetate on remyelination 
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Figure 3 – Effect of Glatiramer Acetate on apoptosis  
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treatment with both high and low doses of anticholinergic medications results in increased 
remyelination, with a higher dose being most effective (Figure 5). However, the model also 
predicts that only low doses are successful in improving remyelination when administered part 
way through disease progression (Figure 5). The model shows that anticholinergics in particular 
have a strong impact on OPC Migration to the site of a lesion (Figure 6). 
 
 
 
 
 
 
 
 
 
Figure 4 – Inhibited M1 receptor complex formation   
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Figure 5 – Anticholinergic effects on remyelination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 –Anticholinergic effects on OPC Migration  
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3.2.3 Cholesterol Synthesis 
The next treatment examined is the use of HMG-CoA Reductase inhibitors, otherwise known as 
statins. There is evidence that the use of statin drugs leads to lower levels of geranylgeranyl 
pyrophosphate, important in the geranylation of proteins, which may be involved in activation of 
phosphatases targeting the p38 MAPK pathway (Paintlia et al., 2010) (Model 4). As of January 
2016, Simvistatin had completed phase II trials in which it was shown to reduce brain atrophy in 
patients with progressive MS (Shirani, Okuda, & Stüve, 2016). Figure 7 confirms the successful 
reduction of geranylgeranyl pyrophosphate upon administration of different dosages of a statin. 
Use of a statin for any dose examined in this model predicts no significant improvement of 
remyelination, with high doses impairing remyelination (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Reduction of geranylgeranyl pyrophosphate formation with statins  
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Figure 8 – Effect of statins on remyelination 
 
3.2.4 Smoothened Receptor Agonists 
It has been noted that activation of RXRγ by binding with 9cRA encourages OPC Differentiation 
(Huang et al., 2010) (Model 7). Furthermore, activation of the smoothened receptor protein 
results in increased expression of RXRγ. For this reason, SMO agonists have been suggested as a 
potential target for MS treatment (Porcu et al., 2015). So far, no trial has been undertaken to 
examine the clinical effectiveness of SMO agonists in multiple sclerosis. Two SMO agonists 
under consideration are clobetasol and halcinonide. Both drugs are corticosteroids currently used 
primarily as topically treatments for certain skin disorders. Addition of a SMO agonist to the 
mathematical model results in an increase in the number of complexes formed between RXRγ 
and 9cRA (Figure 9). The model predicts successful remyelination upon application of a SMO 
agonist (Figure 10). Use of a lower dose of the SMO agonist resulted in more successful 
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remyelination than compared to a higher dose. In addition, administration of the agonist part way 
through the model predicts improved, but less substantial, remyelination compared to full 
treatment.  
  
 
 
 
 
 
 
 
 
Figure 8 – RXRγ/9cRA complex formation in presence of smoothened agonists 
3.2.5 Integrin Signaling 
Evidence has shown the value of immunoglobulin antibodies to target specific proteins to 
promote remyelination. One example is the activation of the β3 integrin protein by rHIgM22. 
This antibody promotes activation of Lyn kinase through integrin signaling (Watzlawik et al., 
2010). As of 2015, rHIgM22 had cleared safety assessment and was awaiting clinical trials 
(Kremer et al., 2015). Implementation of this antibody in the model successfully increases Lyn 
kinase activation, with a larger dose leading to further activation (Figure 10). In addition, the   
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Figure 9 – Effect of smoothened agonists on remyelination 
 
integrin antibody lowered levels of apoptosis (Figure 11). Partial treatment led to the lowest 
levels of apoptosis, with the higher dose reducing levels furthest. Overall, the integrin antibody 
showed improved remyelination, with full treatments showing significant increases in 
remyelination and partial treatments showing a lower, but substantial positive increase in 
remyelination (Figure 12).  
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Figure 9 – Activation of Lyn Kinase in presence of rHIgM22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – Effect of rHIgM22 on apoptosis 
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Figure 11 – Effect of rHIgM22 on remyelination 
 
3.2.6 Sphingosine Receptor  
Activation of the major kinase pathways, including the p38 MAPK and ERK signals, is vital to 
successful OPC differentiation and remyelination. One activator of these pathways in OPCs is 
the sphingosine 1-phosphate receptor (Cui et al., 2014) (Model 11). For this reason, the S1PR 
receptor has become a target of interest in upregulating remyelination. One activator of this 
receptor is the drug fingolimod. Like glatiramer acetate, fingolimod, also known as FTY720, is a 
drug currently in use for the treatment of multiple sclerosis. Fingolimod activates the S1PR 
receptor to encourage the differentiation of OPCs and increase remyelination in in vitro 
experiments (Cui et al., 2014). For these reasons, fingolimod was examined using this 
mathematical model. Figure 12 shows the successful inclusion of fingolimod complexes into the 
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model. Inclusion of fingolimod led to increases in remyelination compared to baseline, with full 
treatment at a higher dose proving the most successful. Furthermore, partial treatment showed 
lower success compared to full treatments, with a higher delayed dose proved more successful at 
remyelination compared to the lower dose (Figure 13). 
 
 
 
 
 
 
 
 
 
Figure 12 – Fingolimod complex formation with S1PR 
3.2.7 Wnt/β-catenin Signaling 
The Wnt/β-catenin signaling pathway plays a complex role in remyelination in which certain 
species may stimulate OPC differentiation, while others inhibit it (Xie, Li, Zhang, & Guan, 
2014) (Model 8). Therefore, modulation of the pathway is a potential target for pharmaceutical 
treatments for remyelination. Indomethacin, a non-steroidal anti-inflammatory drug, is known to 
inhibit the Wnt/β-catenin pathway. Furthermore, experimental evidence suggests that this 
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Figure 13 – Effect of fingolimod on remyelination 
inhibition leads to improved remyelination (Preisner et al., 2015). As of April 2016 there are no 
planned clinical trials for indomethacin with regard to treatment of MS (Kremer et al., 2016). 
Addition of indomethacin increased degradation of β-catenin as modeled (Figure 14). 
Indomethacin also increased overall remyelination in both full treatment states, with a higher 
dose leading to more remyelination. However, the model predicts no change in remyelination 
with addition of a delayed treatment compared to the baseline state (Figure 15).  
Another modulator of Wnt signaling is lithium chloride (LiCl). LiCl is a known stimulator of the 
Wnt signaling pathway, but has other mechanisms of action. LiCl is also known to activate 
Akt/CREB pathways, and has been shown to activate OL expression of MBP and PLP (Meffre, 
Massaad, & Grenier, 2015). Although it is currently used in the treatment of a variety 
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Figure 14 – Indomethacin effect on β-catenin levels 
Figure 15 – Effect of indomethacin on remyelination 
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of neurological disorders, there are no planned clinical trials for LiCl effectiveness in MS. LiCl 
was examined in this model for its overall efficacy towards MS.  Both the Akt/CREB (Figure 16) 
and Wnt (Figure 17) signaling pathways were increased by the addition of LiCl. In addition, 
remyelination was only impacted by full treatment states, with both doses improving 
remyelination (Figure 18). Shifting of partial treatments to earlier time of treatment had no 
effect. For full treatments, the higher dose treatment resulted in lower remyelination than the 
lower dose. For this reason, a third state was added, a larger dose equivalent to 1 nM 
concentration, to determine if there is a point at which the treatment becomes harmful. Figure 19 
demonstrates that there is such a point at which the model predicts administration of LiCl 
reduces remyelination. 
Figure 16 – Activation of Akt signaling in presence of LiCl 
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Figure 17 – Impact of LiCl on levels of β-catenin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 – Effect of LiCl on remyelination 
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Figure 19 – Effect of highest dose of LiCl on remyelination 
 
3.2.8 LINGO-1 
A wide body of MS literature implicates LINGO-1 as a major player preventing proper 
remyelination (Mi et al., 2009; Jepson, et al., 2012; Tran, et al., 2014). As described previously, 
LINGO-1 plays a role in modulating BDNF and p38 MAPK signaling pathways (Mi, Pepinsky, 
& Cadavid, 2013) (Model 4). Therefore, LINGO-1 has become the leading target for use of 
protein antibodies in the treatment of MS. Currently in development, the protein antibody 
BIIB003 finished phase II clinical trials in March 2016 and inhibits LINGO-1 complex 
formation (Kremer et al., 2016). The use of this antibody is thought to be of significant use as a 
supplement to other MS therapies acting on inflammation and the immune system (Kremer et al., 
2016). Addition of BIIB003 to the model predicts significantly greater remyelination for full 
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treatment states, with no significant change for partial treatment states (Figure 20). In addition, 
the antibody impacts remyelination in part by lowering levels of apoptosis (Figure 21).  
     
 
 
 
 
 
 
 
 
Figure 20 – BIIB003 effect on remyelination 
3.3 Mixed Treatments 
To further examined potential pharmaceutical treatments aimed at improving remyelination, 
several combined treatment states were explored. These combined treatment states utilize the 
most effective dose of each drug as described in the results above. The combinations used 
examined drugs unlikely to interact due to operation through separate mechanisms of action.  
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Figure 21 – BIIB003 effect on apoptosis 
 
3.3.1 Glatiramer Acetate + Anticholinergic 
The first combined treatment examined utilized a higher dose of GA and a lower dose of an 
anticholinergic. Results were compared directly with those of the anticholinergic alone. Use of 
both drugs led to significantly reduced levels of apoptosis (Figure 22). The model predicts 
combined use of these drugs in a full treatment state is effective in recovering remyelination 
compared to baseline, but not as effective as only benztropine at its higher dose (Figure 23). 
However, the combined treatment was as effective as low dose benztropine at recovery in a 
partial treatment (Figure 24).   
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Figure 22 – GA and benztropine combined effects on apoptosis 
 
3.3.2 Smoothened Agonist + Fingolimod 
The next combined treatment examined is the use of a SMO agonist (clobetasol or halcinonide) 
with fingolimod. Results were compared directly with those of a SMO agonist. The model 
predicts combined treatment with these two drugs significantly increases rates of OPC migration 
(Figure 25). In addition, this also leads to a predicted decrease in levels of apoptosis (Figure 26). 
Overall, this combination is effective at increasing remyelination in a full treatment state (Figure 
27), but not as successful in a partial treatment state when compared to fingolimod alone (Figure 
28).   
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Figure 23 – GA and benztropine combined effect on remyelination in full treatment state 
Figure 24 – GA and benztropine combined effect on remyelination in partial treatment state  
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Figure 25 – Smoothened agonist and fingolimod effect on OPC Migration 
Figure 26 – Smoothened agonist and fingolimod effect on apoptosis 
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Figure 27 – Smoothened agonist and fingolimod effect on remyelination in full treatment state 
Figure 28 – Smoothened agonist and fingolimod effect on remyelination in partial treatment 
state   
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3.3.3 GA + rHIgM22 
The final combined treatment examined is the use of GA with the integrin antibody rHIgM22. 
The lower dose of integrin antibody was selected as it was more successful than the higher dose 
at stimulating remyelination. The combined treatment was able to significantly lower predicted 
levels of apoptosis (Figure 29). However, full treatment with a combination of these drugs does 
not promote remyelination (Figure 30). Furthermore, partial treatment is not as effective as 
stimulating remyelination as the integrin antibody alone, but is still improved from baseline 
(Figure 31). 
Figure 29  - Combined effect of GA and rHIgM22 on apoptosis  
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Figure 30 – Combined effect of GA and rHIgM22 on remyelination in full treatment state 
Figure 31 – Combined effect of GA and rHIgM22 on remyelination in partial treatment state 
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3.4 New Targets 
Research into remyelination in multiple sclerosis is still a developing field. Most MS treatments 
target the immune response, and do not focus on activation of remyelination. The treatments 
examined above are not in mainstream use for the treatment of MS, and there remains a need for 
new information about pharmaceutical targets which may improve remyelination. Therefore, an 
exploration was undertaken aimed at finding potential pharmaceutical targets by utilizing 
hypothetical drugs in the mathematical model. This hypothetical drug would act to modulate a 
particular reaction through its rate equation. 
3.4.1 Hyaluronic Acid Signaling 
Hyaluronic acid has been described as a blocker of OPC differentiation (Back et al., 2005; 
Sloane et al., 2009). In addition, HA has been shown to improve OPC migration (Piao, Wang, & 
Duncan, 2013). Its presence in myelin lesions has led it to be a suggested target of interest in 
modulating remyelination. Two methods of modulation of HA signaling were examined. The 
first is the inhibition of hyaluronidase, the enzyme cleaving HMW-HA into HA oligomers. Use 
of this inhibitor reduced apoptosis in all cases except for full treatment at high dose in which it 
increased apoptosis (Figure 32). Furthermore, addition of a hyaluronidase inhibitor to the model 
led to increased remyelination in all cases, with higher doses leading to greater remyelination 
(Figure 33).  
A second target considered is the Toll-like receptor 2. TLR2 has been shown to be the receptor 
through which HA operates to inhibit OPC differentiation (Sloane et al., 2009). TLR antagonists 
have been examined for their role in limiting inflammation in diseases such as rheumatoid 
arthritis. Therefore, a TLR2 antagonist was added to the mathematical model to examine its 
efficacy in improving remyelination. Addition of this antagonist greatly lowered levels of 
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apoptosis in all doses (Figure 34). The TLR2 antagonist also improved remyelination in all 
treatment states, and higher doses improved remyelination more than lower doses in both full 
and partial treatment states. (Figure 35). 
  
Figure 32 – Predicted effect of hyaluronidase inhibition on apoptosis of OPCs 
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Figure 33 – Predicted effect of hyaluronidase inhibition on remyelination 
3.4.2 Bone Morphogenic Protein Receptor 
The second target suggested by the model is the BMPR. BMPR activation has been shown to 
inhibit the transcription of myelin basic protein as well as inhibit OPC differentiation (Weng et 
al., 2012; Xie et al., 2014). Currently there is no BMPR antagonist in clinical use. Use of the 
BMPR antagonist predicts increased expression of MBP compared to baseline in full treatment 
states, but not partial treatment states (Figure 36). In addition, there is a significant increase in 
remyelination in full treatment states, but not partial treatment states (Figure 37).   
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Figure 34 – Predicted effect of TLR2 antagonist on apoptosis of OPCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35 – Predicted effect of TLR2 antagonist on remyelination 
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Figure 36 – Predicted effect of BMPR antagonist on MBP expression 
Figure 37 – Predicted effect of BMPR antagonist on remyelination 
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Treatment Full Treatment 
Efficacy 
Partial Treatment 
Efficacy 
Significant Effects 
Glatiramer Acetate 
and Anticholinergic 
Medium Medium Lower levels of 
apoptosis 
Smoothened agonist 
and Fingolimod 
High Medium Slight increase in 
levels of apoptosis 
Glatiramer Acetate 
and rHIgM22 
None Low Lower levels of 
apoptosis 
 
Table 2 – Summary of drug cocktails examined and their efficacy 
 
Target Predicted Full 
Treatment Efficacy 
Predicted Partial 
Treatment Efficacy 
Predicted Significant 
Effects 
Inhibition of 
Hyaluronidase 
Medium Low Lower levels of 
apoptosis at low doses 
TLR2 
Antagonism 
High High Lower levels of 
apoptosis, higher 
doses less effective 
BMPR 
Antagonism 
High None MBP expression 
increase 
 
Table 3 – Summary of theoretical drug treatments for improving remyelination in MS  
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4. Discussion 
4.1 Baseline/Disease State 
The baseline state model properly mimics the current view of remyelination in MS, with 
particular regard for relapsing-remitting MS. For all positive, major contributing factors to 
remyelination there is a period of little change followed by short term successful increase in the 
form of brief spikes, followed by a predicted decline over the long term, while maintaining the 
spiking pattern. These results correlate strongly to the pathology of relapsing-remitting MS. MS 
pathology would show a period of demyelination in which the body would be slow to respond, 
followed by some successful remyelination which then fails over the long term. All major myelin 
proteins (MBP, PLP, and CNPase) follow this pattern, as does OPC migration, OPC 
differentiation, and overall remyelination. Counter to this, levels of apoptosis rise in the baseline 
state, which could be a driving force in the overall failure of remyelination.  
4.2 Treatment State 
Use of this mathematical model presents several treatment options which predict improvement of 
remyelination for multiple sclerosis. Glatiramer acetate, anticholinergics, statins, rHIgM22, 
fingolimod, indomethacin, lithium, and BIIB003 all show some form of efficacy in improving 
remyelination in MS (Table 1). Glatiramer acetate, already used in MS treatment, upregulates 
immune expression of certain neurotrophic factors for differentiating OPCs. The success of a 
higher dose offers encouragement that early use of glatiramer acetate could significantly improve 
remyelination. However, the more realistic delayed treatment scenarios improve remyelination 
only slightly, and also slightly increase rates of apoptosis. This increase in apoptosis may be in 
part related to the release of PDGF by Th2 cells, which has been shown to prevent slow 
differentiation and encourage cell division, leaving OPCs vulnerable to further inflammation 
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before eventually differentiating. Therefore, this implies glatiramer acetate may be only partially 
successful in improving remyelination. 
Anticholinergic drugs, like benztropine and clemastine, provide some of the best improvement 
predicted in the model for remyelination. Anticholinergics influence the activity of several 
pathways including the expression of several other receptors (Model 5). The use of a low dose 
anticholinergic would be favorable not only because of the success of a lower dose partial 
treatment predicted by this model, but also due to the possibility in avoiding certain side effects. 
Overall, the improvement in remyelination, and particularly OPC migration, presented by 
anticholinergics makes them an important target for consideration. 
Despite some evidence that use of statin drugs may improve overall remyelination, this model 
predicts little success in use of a statin. Partial treatment demonstrated no significant change 
from baseline, while high dose usage was predicted to encourage demyelination. Statin drugs 
block the HMG-CoA reductase enzyme, important in production of cholesterol, a vital part of 
myelin. This model predicts any benefit gained from limiting these lipids in their use for 
modifying proteins is outweighed by the harm this does in shrinking the pool of lipids for myelin 
production. 
Smoothened receptor agonists, including halcinonide and clobetasol, improve overall expression 
of RXRγ. There was clear effectiveness of these agonists in overall improvement of 
remyelination. In particular, this treatment strategy showed some of the greatest success in 
partial treatment states. This success marks SMO agonists as a key target for future examination 
of remyelination in MS. 
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Use of the integrin receptor subunit antibody rHIgM22 in the model predicts sustained successful 
remyelination compared to baseline. rHIgM22 exerts its effects by leading to downstream 
phosphorylation of the Lyn kinase, which suppresses apoptosis through inactivation of caspases. 
The results point to a use of low dose antibody being more effective than higher dose, but with 
both providing improved remyelination and reduced levels of apoptosis. In addition, the use of 
the antibody in a partial treatment state also predicts more successful remyelination and lowered 
apoptosis compared to baseline, presenting this antibody as another target for consideration in 
improving remyelination in MS. 
The model predicts that use of the sphingosine receptor agonist fingolimod improves 
remyelination in all treatment states considered. Fingolimod’s action at this receptor leads to 
downstream activation of major kinase pathways, including the p38 MAPK and ERK pathways, 
and resulting in OPC differentiation. The success of fingolimod in both full and partial treatment 
states implicates it as yet another strong target for consideration in the treatment of MS. 
However, the use of a higher dose in the partial treatment state is less effective than that of a 
lower dose, providing unclear evidence of the efficacy of a particular dose in the more realistic 
partial treatment model. 
Modulators of Wnt/β-catenin signaling provide some evidence for successful improvement of 
remyelination. Indomethacin, an inhibitor of this signaling pathway improves remyelination in 
full treatment states, with a higher dose proving more successful than a lower dose. A stimulator 
of this pathway, treatment with lithium leads to improved protein kinase B signaling and 
increased remyelination. However, higher doses of lithium can cause the opposite effect, 
resulting in decreased remyelination. In addition, neither treatment impacted remyelination in 
partial treatment states. This implies the action of the Wnt/β-catenin pathway is exerted early in 
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OPC differentiation, and may not make this pathway an ideal aim for examining potential 
remyelination treatments. Furthermore, because of lithium’s potential to decrease remyelination 
in high doses, it is unclear whether this efficacy at low doses will correlate with success in the 
form of an actual treatment. 
Use of the LINGO-1 antibody BIIB003 resulted in lower levels of apoptosis and improved 
remyelination in full treatment states. The LINGO-1 receptor is involved in a number of cell 
surface interactions, most of which are implicated in inhibiting important cell signals (Model 4). 
However, while full treatment with LINGO-1 antibody was successful, there was no significant 
change predicted in partial treatment states. As LINGO-1 is involved in an OPC-neuron 
interaction, it is likely to take place soon after demyelination. Therefore, it may be difficult to act 
on LINGO-1 prior to it exerting its effects on the first set of OPC’s to respond. However, the 
antibody could act on any subsequent demyelination, and for this reason BIIB003 may be a 
valuable target for improving remyelination. 
Several combined treatment states were analyzed for potential success of drug cocktails in 
increasing remyelination. The first cocktail combined the effects of glatiramer acetate, to 
improve immune signals, and anticholinergics, to improve receptor expression. This cocktail 
lowered levels of apoptosis in a full treatment state, and improved remyelination overall in a full 
treatment state, though not at the level of an anticholinergic alone. However, unlike the 
anticholinergic alone, partial treatment with the first cocktail improved remyelination more 
efficiently. This difference may involve stimulation of PDGF expression in the presence of GA, 
which encourages OPC proliferation over differentiation. This is seen in treatment with GA 
alone, which saw a delay in remyelination for high dose full treatments before becoming the 
most successful trial for GA. Furthermore, it may implicate GA as a treatment which exerts some 
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negative effects on remyelination, but has an overall net positive effect. Success in the partial 
treatment model for the GA and anticholinergic, the most accurate reflection of treating a patient, 
implicates this cocktail as one for consideration in remyelination. The second cocktail used a 
smoothened receptor agonist and fingolimod, to upregulate active kinase levels. This second 
cocktail did recover remyelination in a full treatment state, but was not very effective in the 
partial treatment state. In addition, this partial treatment surprisingly increased levels of 
apoptosis, implying the second cocktail is not an ideal mixture of treatments for remyelination. 
The final cocktail combined glatiramer acetate and rHIgM22, to increase anti-apoptotic Lyn 
kinase. This cocktail was successful in lowering levels of apoptosis, but failed at improving 
remyelination in a full treatment state. This effect is likely similar to the actions of GA 
mentioned previously. However, it slightly recovered remyelination in a partial treatment state. 
Therefore, the efficacy of this final cocktail is likely mixed, with some potential for treatment of 
remyelination. 
Two new targets for remyelination were examined using the model designed here (Table 3). The 
first, hyaluronic acid signaling was modulated with inhibition of hyaluronidase and inhibition of 
TLR2. Inhibition of hyaluronidase resulted in increased remyelination in all treatment states, but 
with increased apoptosis in a full treatment at high dose. Therefore, there is promise for 
inhibition of hyaluronidase in some low dose capacity. TLR2 antagonism also resulted in 
recovery of remyelination, but this time in all treatment states. In addition, levels of apoptosis 
were significantly reduced in all treatment states. This implicates TLR2 as a target for 
consideration in improvement of remyelination in MS. Finally, the use of a BMPR antagonist 
improved expression of MBP in the mathematical model and led to improved levels of 
remyelination. However, partial treatment states showed no significant improvement, implying 
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that any targeting of BMPR would need to be early in pathology. This result does provide 
promise for the targeting of signaling related to BMPR, as its mechanisms of action to modulate 
MBP expression become more clear. Overall, the model successfully predicts the actions of 
potential MS treatments for remyelination, and is useful in exploring future targets for 
examination of remyelination.  
 
5. Conclusion 
This paper describes the production of a testable, mathematical model of remyelination in 
multiple sclerosis. Models of this nature provide a convenient and efficient method for 
examining potential efficacy of pharmaceutical treatments for multiple sclerosis. The model 
consists primarily of two distinct, but related, processes: OPC differentiation and the production 
of myelin components. The former process is upregulated by the presence of certain transcription 
factors, and inhibited by OPC proliferation. Remyelination overall is then considered based on 
the successful production of myelin components, while also taking into account the roles of OPC 
migration and apoptosis. The baseline model comparing a disease and healthy state accurately 
reflects a course of relapsing-remitting multiple sclerosis, with occasional spikes of 
remyelination which fail over time. Overall, the model examines the effectiveness of multiple 
treatments aimed at stimulating and promoting remyelination in multiple sclerosis. These 
treatments include those already in use, some in clinical trial, some in consideration for clinical 
trial, and drug cocktails. Furthermore, this model is also able to suggest targets for future 
evaluation in their efficacy in improving remyelination. Treatment results reinforce ideas of early 
diagnosis and treatment, as delayed treatment scenarios most often show lower predicted 
remyelination than full treatment states. Several of these drugs represent approaches which could 
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improve the failing remyelination pathway present in multiple sclerosis, and should be seriously 
considered for clinical trial. 
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Appendix – MATLAB Code 
Equations and Initial Conditions 
(example shown is for partial treatment state where G = 0.01 at t=75) 
function [dx] = RemyelinationBackupHalfTreat_eq(t,X) 
 
% Make rate constants and independent variables global variables 
global k Xind B C D E F G I K W Y Z A1 A2 
 
tTreat = 75; 
 
if t < tTreat 
    G = 0; 
 
else 
    G = 0.01; 
end 
 
X0 = zeros(412,1); 
 
k = zeros(153,1); 
 
Xind = zeros (140,1); 
 
 
tspan= 0:0.01:120; 
 
% Write inital concentrations for the dependent variables (in CellDesigner 
% any species that has an arrow pointing toward it). Use comments to keep 
% track of species identities. 
 
%KEEP IN nM concentrations, 10 used as placeholder 
%Program used on calculator to convert PPM from PaxDB to nM 
%Keep in scientific notation to two decimal places 
 
%ASSUMPTION CODE A = Must decide if concentration of phosphorylated protein 
%is zero or not 
%ASSUMPTION CODE B = Vague concept given placeholder value 
%ASSUMPTION CODE C = Complex given placeholder of 10 
 
X0(135) = 1.41e3;  %Contactin2 
X0(136) = 6.81;    %NT-3 
X0(137) = 10;      %Hyaluronic Acid (PLACEHOLDER) 
X0(138) = 3.16e2;  %TNFa (averaged several whole organism values) 
X0(139) = 7.44e3;  %PTN 
X0(140) = 4.34e-1; %HB-EGF 
X0(141) = 4.34e2;  % TGFa 
X0(142) = 10;      % TGF Complex (%ASSUMPTION CODE C) 
X0(143) = 6.28e1;  % Jagged1 
X0(144) = 10;      % Tnfa/TnfR2 Complex (ASSUMPTION CODE C) 
X0(145) = 6.63e1;  % CNTF 
X0(146) = 4.5e1;   % ET-1 (averaged several whole organism values) 
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X0(147) = 2.36e2;  % TnC (used Brain integrated value) 
X0(148) = 1.54e3;  % FGF2 
X0(149) = 10;      % PDGF (astro) (sort of assuming there is none being produced, no 
brain measurements were available, average whole organism value is 1.4e2) 
X0(150) = 10;      % p85-P (ASSUMPTION CODE A) 
X0(151) = 10;      % PIP3 (astro) 
X0(152) = 10;      % Pdk1 active (astro) 
X0(153) = 1.03e1;  % Nf-kB (astro) 
X0(154) = 1.03e2;  % IkB (astro) 
X0(155) = 10;      % Akt -P (astro) (ASSUMPTION CODE A) 
X0(156) = 3.83e3;  % CXCL12 (USED SPINAL CORD DATA) 
X0(157) = 5.00;    % LIF 
X0(158) = 10;      % HA/CD44 Complex (%ASSUMPTION CODE C) 
X0(159) = 10;      % OPC Proliferation(ASSUMPTION CODE B) 
X0(160) = 10;      % OPC Differentiation (ASSUMPTION CODE B) 
X0(161) = 10;      % Laminin/aV Complex (%ASSUMPTION CODE C) 
X0(162) = 10;      % TnC/aV Complex (%ASSUMPTION CODE C) 
X0(163) = 10;      % FGF2/R Complex (%ASSUMPTION CODE C) 
X0(164) = 10;      % PDGF/R Complex (%ASSUMPTION CODE C) 
X0(165) = 10;      % CXCL12/R4 Complex (%ASSUMPTION CODE C) 
X0(166) = 10;      % LIF/gp130 Complex (%ASSUMPTION CODE C) 
X0(167) = 10;      % CNTF/gp130 Complex (%ASSUMPTION CODE C) 
X0(168) = 10;      % TNFa/DR6 Complex (%ASSUMPTION CODE C) 
X0(169) = 10;      % TLR2/MyD88 Complex (%ASSUMPTION CODE C) 
X0(170) = 10;      % TLR2/MyD88/HA Complex (%ASSUMPTION CODE C) 
X0(171) = 5.61e-2; % Laminin (Assumed laminin 1 trimer of alpha, beta, gamma subunits, 
used lowest ppm of three subunits and full total mass) 
X0(172) = 10;      % Contactin 1 (PLACEHOLDER) 
X0(173) = 10;      % L1 (PLACEHOLDER) 
X0(174) = 10;      % Laminin/a6B1 Complex (%ASSUMPTION CODE C) 
X0(175) = 10;      % TnR/aV integrin Complex (%ASSUMPTION CODE C) 
X0(176) = 3.49e3;  % TnR 
X0(177) = 10;      % PDGFR-P (PLACEHOLDER) 
X0(178) = 10;      % gp130-P (PLACEHOLDER) 
X0(179) = 10;      % JAK2 active 
X0(180) = 10;      % IL6/IL6R Chimera 
X0(181) = 1e10;      % OPC Migration (ASSUMPTION CODE B) 
X0(182) = 10;      % EGFR-P 
X0(183) = 10;      % PDGF (Th2) (See assumption in X149) 
X0(184) = 10;      % BDNF (Th2) (Being given placeholder of 10 because of confusion 
with X301) 
X0(185) = 10;      % ILK/Parvin Complex (%ASSUMPTION CODE C) 
X0(186) = 10;      % Akt-P (OPC) (%ASSUMPTION CODE A) 
X0(187) = 10;      % Fyn-P (OPC) (%ASSUMPTION CODE A) 
X0(188) = 1.70e3;  % Fyn (OPC) 
X0(189) = 10;      % Wave2-P (%ASSUMPTION CODE A) 
X0(190) = 10;      % p38 MAPK-P 
X0(191) = 10;      % p39/Cdk5 Complex (%ASSUMPTION CODE C) 
X0(192) = 10;      % Cdk5-P (%ASSUMPTION CODE A) 
X0(193) = 10;      % p25/CDK Complex (%ASSUMPTION CODE C) 
X0(194) = 10;      % STAT3-P 
X0(195) = 10;      % STAT1-P 
X0(196) = 0.18;    % Caspase 8 
X0(197) = 0.1;     % Caspase 3 
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X0(198) = 10;       % Apoptosis (ASSUMPTION CODE B) (10) 
X0(199) = 10;      % Tiam1-P (%ASSUMPTION CODE A) 
X0(200) = 10;      % Rac1 GTP (%ASSUMPTION CODE A) 
X0(201) = 10;      % HMW-HA (PLACEHOLDER) 
X0(202) = 10;      % Jagged1/Notch1 Complex (%ASSUMPTION CODE C) 
X0(203) = 10;      % PTPRZ inactive (PLACEHOLDER) 
X0(204) = 10;      % CSL active (ASSUMPTION CODE A) 
X0(205) = 10;      % contactin1/Notch1 Complex (ASSUMPTION CODE C) 
X0(206) = 10;      % miRNA/Rik complex (ASSUMPTION CODE C) 
X0(207) = 5.98e2;  % Bcl-2 (Used spinal cord data) 
X0(208) = 10;      % Bcl-2/BAD complex (ASSUMPTION CODE C) 
X0(209) = 10;      % Deltex active (ASSUMPTION CODE A) 
X0(210) = 4.44e3;  % IGF-1 (Th2 cell) 
X0(211) = 1.62e1;  % IGF/R Complex 
X0(212) = 10;      % PI3K Active (OPC) (ASSUMPTION CODE A) 
X0(213) = 10;      % RXRy Complex (ASSUMPTION CODE C) 
X0(214) = 1.97e1;  % FGFR1 
X0(215) = 10;      % Wnt/LRP Complex (ASSUMPTION CODE C) 
X0(216) = 10;      % Tcf4/B-catenin complex (ASSUMPTION CODE C) 
X0(217) = 10;      % TSC2-P (ASSUMPTION CODE A) 
X0(218) = 1.58e4;  % Rheb GDP 
X0(219) = 10;      % Rheb GTP (ASSUMPTION CODE A) 
X0(220) = 1.87e2;  % TrkC 
X0(221) = 10;      % PDK1 active (OPC) (ASSUMPTION CODE C) 
X0(222) = 10;      % Rik siRNA (PLACEHOLDER) 
X0(223) = 10;      % Ascl1 (PLACEHOLDER) 
X0(224) = 10;      % BAD-P (ASSUMPTION CODE A) 
X0(225) = 10;      % Cyt C in Cyto 
X0(226) = 10;      % Caspase 9 (PLACEHOLDER) 
X0(227) = 10;      % Cdc42 GTP (ASSUMPTION CODE A) 
X0(228) = 10;      % IgG/FcRy complex (ASSUMPTION CODE C) 
X0(229) = 10;      % BDNF/TrkB complex (ASSUMPTION CODE C) 
X0(230) = 10;      % Laminin/Dystoglycan complex (ASSUMPTION CODE C) 
X0(231) = 10;      % MNK-P (ASSUMPTION CODE A) 
X0(232) = 10;      % GSK3B inactive (ASSUMPTION CODE A) 
X0(233) = 10;      % b-catenin degraded (ASSUMPTION CODE A) 
X0(234) = 1.85e1;  % Olig2 
X0(235) = 10;      % mTOR1 -P (ASSUMPTION CODE A) 
X0(236) = 10;      % S6K - P (ASSUMPTION CODE A) 
X0(237) = 3.54e2;  % p190RhoGAP 
X0(238) = 10;      % p190RhoGAP-P (ASSUMPTION CODE A) 
X0(239) = 5.36e4;  % RhoA GDP 
X0(240) = 10;      % RhoA GTP (ASSUMPTION CODE A) 
X0(241) = 10;      % Caspase 9-P (ASSUMPTION CODE A) 
X0(242) = 10;      % CREB-P (ASSUMPTION CODE A) 
X0(243) = 7.27e2;  % aV integrin 
X0(244) = 2.35;    % Axin2 
X0(245) = 1.63e1;  % Sip1 
X0(246) = 6.03;    % MRF 
X0(247) = 3.16e2;  % Akt (astro) 
X0(248) = 10;      % IL-17 complex (ASSUMPTION CODE C) 
X0(249) = 10;      % ERK1/2-P (ASSUMPTION CODE A) 
X0(250) = 8.74e1;  % YY1 
X0(251) = 1;       % O4 (can't find data) 
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X0(252) = 1;       % O1 (can't find data) 
X0(253) = 5.10e2;  % Cdk4 
X0(254) = 1.62e2;  % p21 (whole organism data) 
X0(255) = 3.23e3;  % p27 
X0(256) = 7.31e2;  % PTEN 
X0(257) = 10;      % PLP/AMPA/integrin complex (ASSUMPTION CODE C) 
X0(258) = 10;      % PKA active (ASSUMPTION CODE A) 
X0(259) = 10;      % cAMP 
X0(260) = 10;      % AMP 
X0(261) = 10;      % AMPK active (ASSUMPTION CODE C) 
X0(262) = 10;      % PPARy Free 
X0(263) = 10;      % cPLA2-P (ASSUMPTION CODE C) 
X0(264) = 10;      % RhoA/ROCK Complex (ASSUMPTION CODE C) 
X0(265) = 10;      % p75/Ngr1/LINGO complex (ASSUMPTION CODE C) 
X0(266) = 1.62e1;  % IGFR1 
X0(267) = 1e4;      % Mevalonate 
X0(268) = 1e4;      % Mevalonate Phosphate 
X0(269) = 1e4;      % Mevalonate PP 
X0(270) = 1e4;      % Isopentyl PP 
X0(271) = 1e4;      % Farnesyl PP 
X0(272) = 1e4;      % geranylgeranyl PP 
X0(273) = 1e4;      % Squalene 
X0(274) = 10;      % NRG1/ErB3 complex (ASSUMPTION CODE C) 
X0(275) = 10;      % NRG1/ErB4 complex (ASSUMPTION CODE C) 
X0(276) = 5.49e-1; % HES5 
X0(277) = 1.03e1;  % NF-kB (OPC) 
X0(278) = 1.03e2;  % IkB (OPC) 
X0(279) = 10;      % ENV/TLR4 complex (ASSUMPTION CODE C) 
X0(280) = 7.08;    % RXRy (used spinal cord data) 
X0(281) = 0;       % Clobetasol/Smoothened complex 
X0(282) = 0;       % Halcinonide/Smoothened complex 
X0(283) = 7.22;    % ErB3 
X0(284) = 5.59;    % ErB4 
X0(285) = 3.66e1;  % PDGFRa 
X0(286) = 10;      % Adenylate Cyclase active (ASSUMPTION CODE A) 
X0(287) = 10;       % MBP mRNA 
X0(288) = 1.48e1;  % Notch1 
X0(289) = 10;      % M1/Ach complex (ASSUMPTION CODE C) 
X0(290) = 10;      % M3/Ach complex (ASSUMPTION CODE C) 
X0(291) = 10;      % M2/Ach complex (ASSUMPTION CODE C) 
X0(292) = 10;      % M4/Ach complex (ASSUMPTION CODE C) 
X0(293) = 10;      % S1P complex (ASSUMPTION CODE C) 
X0(294) = 0;       % FTY720 complex 
X0(295) = 0;       % FTY720-P 
X0(296) = 0;       % rHIgM22 antibody compkex 
X0(297) = 10;      % Lyn-P (ASSUMPTION CODE A) 
X0(298) = 10;      % MYRF-N terminus 
X0(299) = 10;      % Nkx2.2/HDAC1/Sin3a (ASSUMPTION CODE C) 
X0(300) = 10;      % MeCP2/HDAC1/sin3a (ASSUMPTION CODE C) 
X0(301) = 10;      % BDNF (OPC) (Being given placeholder of 10 because of confusion 
with X184) 
X0(302) = 2.62;    % Sp5 
X0(303) = 10;       % MAG mRNA 
X0(304) = 7e3;       % MAG 
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X0(305) = 8e2;       % MPZ 
X0(306) = 10;      % Sp1-P (ASSUMPTION CODE A) 
X0(307) = 10;      % 4EBP1-P (ASSUMPTION CODE A) 
X0(308) = 10;      % 4eEBP1/eIF4E complex (ASSUMPTION CODE C) 
X0(309) = 10;      % eIF4E-P (ASSUMPTION CODE A) 
X0(310) = 10;      % BMP4/R complex (ASSUMPTION CODE C) 
X0(311) = 10;      % Smad1-P (ASSUMPTION CODE C) 
X0(312) = 10;      % Egr2 (COULD NOT FIND DATA, 2.07e1 IS WHOLE ORGANISM VALUE) 
X0(313) = 10;      % EPO/R complex (ASSUMPTION CODE C) 
X0(314) = 10;       % MOG mRNA 
X0(315) = 8e4;       % MOG 
X0(316) = 5e5;       % PLP 
X0(317) = 10;      % Smad7 (COULD NOT FIND DATA, 4.52 IS WHOLE ORGANISM VALUE) 
X0(318) = 10;      % Olig1/Sox10 complex (ASSUMPTION CODE C) 
X0(319) = 0;       % MBP mRNA translocated 
X0(320) = 2.54E2;  % SOX 10 
X0(321) = 10;      % MEK-P (ASSUMPTION CODE A) 
X0(322) = 10;      % glutamate/NMDA complex (ASSUMPTION CODE C) 
X0(323) = 10;      % Raf/Ras GTP complex (ASSUMPTION CODE C) 
X0(324) = 10;      % Ras GTP (ASSUMPTION CODE A) 
X0(325) = 6e5;       % MBP 
X0(326) = 10;      % SR6P-P (ASSUMPTION CODE A) 
X0(327) = 10;      % Olig1 (USED RETINA DATA) 
X0(328) = 10;      % Smad7/Smurf1 complex (ASSUMPTION CODE C) 
X0(329) = 1e5;       % CNPase 
X0(330) = 10;       % PLP mRNA 
X0(331) = 2.88e4;  % hnRNP A2 
X0(332) = 10;      % L1/contactin2 complex (ASSUMPTION CODE C) 
X0(333) = 10;      % NT-3/TrkC complex (ASSUMPTION CODE C) 
X0(334) = 0;       % Remyelination 
X0(335) = 10;      % IkB degraded (astro) 
X0(336) = 10;      % IkB degraded (OPC) 
X0(337) = 10;      % TNFR2 (astro) (no data found, whole organism 7.06e1) 
X0(338) = 10;      % CXCR4 (no data found, 1.12e2 whole organism) 
X0(339) = 1.53e2;  % a6B1 integrin 
X0(340) = 9.91e2;  % ILK 
X0(341) = 9.18e1;  % Parvin (used parvin beta) 
X0(342) = 1.85e1;  % gp130 
X0(343) = 4.18;    % DR6 
X0(344) = 1.31e3;  % CD44 
X0(345) = 4.45e1;  % TLR2 
X0(346) = 6.02e2;  % MyD88 (spinal cord data) 
X0(347) = 10;      % NMDAR (data not found) 
X0(348) = 10;      % Glutamate 
X0(349) = 4.81e2;  % IgG 
X0(350) = 1.28e1;  % FcRy 
X0(351) = 2.3e3;   % PKA 
X0(352) = 10;      % TGFB1 (data not found) 
X0(353) = 10;      % TGFBR2 (astro) (datanot found) 
X0(354) = 8.75e2;  % TrkB 
X0(355) = 10;      % p39 (whole organism value is 1.02e2) 
X0(356) = 2.50e2;  % p25 (used value for CDKR1) 
X0(357) = 7.34;    % miRNA-23A 
X0(358) = 8.37e3;  % BAD 
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X0(359) = 10;      % AMPA (placeholder) 
X0(360) = 10;      % 9cRA (placeholder) 
X0(361) = 3.81;    % Wnt-3a 
X0(362) = 5.58e-2; % LRP5/6 
X0(363) = 4.74e3;  % B-catenin 
X0(364) = 1.04e1;  % Tcf4 
X0(365) = 3.78e2;  % Dystoglycan 
X0(366) = 5.15e5;  % PLP (extracellular) 
X0(367) = 2.06e1;  % IL-17A 
X0(368) = 1.04;    % IL-17RA 
X0(369) = 1.80e3;  % AMPK 
X0(370) = 1.11e3;  % ROCK II 
X0(371) = 8.40e2;  % LINGO1 
X0(372) = 2.01e4;  % Erb2 
X0(373) = 0;  % p75 
X0(374) = 10;      % NRG1-Type III (no data) 
X0(375) = 0;       % ENV (SPECIFIC VIRAL INFECTION) 
X0(376) = 1.10e1;  % TLR4 
X0(377) = 4.28e2;  % M1 
X0(378) = 2.93e2;  % M3 
X0(379) = 8.88e1;  % M2 
X0(380) = 1.89e-1; % M4 
X0(381) = 10;      % Acetylcholine 
X0(382) = 10;      % S1P (placeholder) 
X0(383) = 4.13e2;  % S1P1 
X0(384) = 1.29e1;  % mSin3a 
X0(385) = 1.68e2;  % HDAC1 
X0(386) = 4.41e3;  % MeCP2 
X0(387) = 1.89e1;  % Nkx2.2 (used retina) 
X0(388) = 8.35e3;  % 4EBP1 
X0(389) = 1.28e5;  % eIF4E 
X0(390) = 10;      % BMP4 (whole organism is 3.65) 
X0(391) = 6.99e1;  % BMPR 
X0(392) = 10;      % EPO (whole organism is 2.32e2) 
X0(393) = 2.18;    % EPOR 
X0(394) = 1.49e1;  % Smurf1 
X0(395) = 1.10e2;  % Raf 
X0(396) = 3.16e2;  % Akt (OPC) 
X0(397) = 1.77e2;  % p38 MAPK (Used MAPK11) 
X0(398) = 4.75e-1; % PI3K inactive 
X0(399) = 1.07e3;  % PDK1 inactive (OPC) 
X0(400) = 2.18e4;  % ERK1/2 (added sum of ERK1 and ERK 2 aka MAPK3 and MAPK1) 
X0(401) = 2.14;    % MNK (used spinal cord) 
X0(402) = 7.51e1;  % mTOR1 
X0(403) = 1.77e4;  % MEK 
X0(404) = 1.07e3;  % PDK1 inactive (astro) 
X0(406) = 10; %Adenosine relased 
X0(407) = 16.63; %P1 receptor (A2A) 
X0(408) = 10; %Adenosine Complex 
X0(410) = 10; %UDP released 
X0(411) = 7.81; %GPR17 
X0(412) = 10; %UDP complex 
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% Write inital concentrations for the independent variables (in 
% CellDesigner any species that does not have an arrow pointing toward it) 
%Placeholder values are at a standard of 1 
%Genes were eyeballed more or less using the NCBI Geo profiles graphs 
%ASSUMPTION ISSUE D refers to the use of rat profile comparing OPC to Olig 
%which is based off of a ratio of 1 
 
Xind(1) = 10;        % Demyelination 
Xind(2) = 0.1;        % OPC Not Migrated 
Xind(3) = 1;        % Living Cell 
Xind(4) = 10;       % Jagged1 gene (astro) (323.5) 
Xind(5) = 10;       % TNFR2 (astro) (data not found, whole organism is 7.06e1) 
Xind(6) = 10;       % CNTF gene (astro) (14.6) 
Xind(7) = 10;       % ET-1 gene (astro) (6.24) 
Xind(8) = 10;     % TNC gene (astro) (2234) 
Xind(9) = 10;    % FGF2 gene (astro) (123.2) 
Xind(10) = 10;    % PDGF gene (astro) (2659) 
Xind(11) = 5.96e2;  % p85 (astro) 
Xind(12) = 10;      % PIP2 (astro) (placeholder) 
Xind(13) = 6.20e2;  % Adenylate cyclase inactive (sum of ADCY1,2, and 8) 
Xind(14) = 10;      % NF-kB/IkB complex (astro) (Placeholder) 
Xind(15) = 10;   % ErB4 gene (0.545) 
Xind(16) = 10;    % CXCL12 gene (astro) (4046) 
Xind(17) = 10;    % LIF gene (astro) (43.9) 
Xind(18) = 1;       % OPC Non-Proliferating 
Xind(19) = 10;    % PDGFRa gene (4.47) 
 
Xind(20) = 10;     % Olig1 gene (2e4) 
Xind(21) = 10;   % Ascl1 gene (1.3e3) 
Xind(22) = Z;       % Indometacin 
Xind(23) = 1.10e4;  % PTPa 
Xind(24) = 0;       % Monocycline 
Xind(25) = 1;       % Demyelinated Lesion 
Xind(26) = 10;      % IL-1B (data not found whole organism value 1.79e1) 
Xind(27) = 10;      % Hyaluronidase (data not found whole organism values 2.61e1) 
Xind(28) = G;       % Halcinonide 
Xind(29) = 10;      % Laminin blocked (PLACEHOLDER) 
Xind(30) = 2.77e3;  % L1 blocked 
Xind(31) = 1.05e4;  % contactin blocked 
Xind(32) = 9.70e2;  % Lamin B 
Xind(33) = 10;       % TnR gene (ASSUMPTION ISSUE D) (1) 
Xind(34) = 1.61;    % JAK2 inactive 
Xind(35) = 1.18e1;  % IL-6 
Xind(36) = 10;      % sIL-6R (whole organism value is 2.08e1) 
Xind(37) = 2.96e2;  % EGFR 
Xind(38) = 10;    % PDGF gene (Th2) (11.9) 
Xind(39) = 10;     % BDNF gene (Th2) (4.5) 
Xind(40) = 3.70e3;  % HDAC11 
Xind(41) = 9.15e3;  % H3 (HIST1H3A was what was used) 
Xind(42) = B;       % Glatiramer Acetate 
Xind(43) = C;       % Benztropine 
Xind(44) = 5.78e2;  % Wave2 
Xind(45) = 3.31e2;  % Sphk2 
Xind(46) = 10;     % PLP gene (ASSUMPTION ISSUE D) (3.5) 
92 
 
Xind(47) = 9.97e3;  % Cdk5 
Xind(48) = 10;       % CNPase gene (ASSUMPTION ISSUE D) (7) 
Xind(49) = 6.52e2;  % STAT3 
Xind(50) = 7.73e2;  % STAT1 
Xind(51) = 10;      % Procaspase8 (PLACEHOLDER) 
Xind(52) = 1.99e2;  % Procaspase3 (1.99e2) 
Xind(53) = 5.04e1;  % Tiam1 
Xind(54) = 4.04e4;  % Rac1 GDP 
Xind(55) = 4.93e1;  % Sox2 
Xind(56) = 1.32e3;  % PTPRZ active 
Xind(57) = 2.66e1;  % CSL inactive 
Xind(58) = 10;    % Smad7 gene (ASSUMPTION ISSUE D) (1.20) 
Xind(59) = 10;      % T3 (placeholder) 
Xind(60) = 10;    % Bcl-2 gene (no real data found, used rat choroid plexus data) 
(5.67) 
Xind(61) = 1.04;    % Deltex inactive (used retinal data) 
Xind(62) = 10;    % IGF-1 gene (Th2) (31.3) 
Xind(63) = Y;       % FTY720 
Xind(64) = 10;      % p57kip2 (whole organism is 4.26e1) 
Xind(65) = 10;    % FGFR1 gene (ASSUMPTION ISSUE D) (1.11) 
Xind(66) = 8.96e3;  % S6RP 
Xind(67) = 2.88e4;  % hnRNPA2 
Xind(68) = 5.37e2;  % TOG 
Xind(69) = 10;      % sncRNA715 (placeholder) 
Xind(70) = 1.44e2;  % TSC2 
Xind(71) = 10;    % Notch1 gene (astrocyte t antigen inactivation value) (78.2) 
Xind(72) = 10;      % Rik gene (placeholder) 
Xind(73) = 7.94e3;  % Ras GDP 
Xind(74) = 1.67e5;  % Cyt in Mito 
Xind(75) = 1.34e3;  % Bax 
Xind(76) = 10;      % Procaspase9 (1.04e2) 
Xind(77) = 4.25e4;  % Cdc42 GDP 
Xind(78) = F;       % Clobetasol 
Xind(79) = 10;    % RXRy gene (ASSUMPTION ISSUE D) (0.98) 
Xind(80) = 6.09e3;  % Transferrin 
Xind(81) = 10;    % Sox10 gene (ASSUMPTION ISSUE D) (5.44) 
Xind(82) = 1.26e1;  % Gtx (used whole organism data because it is oligodendrocyte 
specific) 
Xind(83) = 2.35e3;  % GSK3B 
Xind(84) = A1;      % LiCl 
Xind(85) = 10;   % Olig2 gene (ASSUMPTION ISSUE D) (1.456) 
Xind(86) = 2.95e4;  % Pur-a 
Xind(87) = 1.21e2;  % S6K 
Xind(88) = 6.25;    % Dvl-2 
Xind(89) = 10;      % Dkk1 (whole organism is 3.10e1) 
Xind(90) = 2.71e2;  % CREB (used CREB1) 
Xind(91) = 10;   % ITGAV gene (ASSUMPTION ISSUE D) (1.273) 
Xind(92) = 2.35;    % Axin2 
Xind(93) = 10;   % Sip1 gene (ASSUMPTION ISSUE D) (1.552) 
Xind(94) = 10;       % MRF gene (ASSUMPTION ISSUE D) (7) 
Xind(95) = 1.18e4;  % MAPt 
Xind(96) = 4.47e1;  % Kif1b 
Xind(97) = 10;      % MOG gene (ASSUMPTION ISSUE D) (26) 
Xind(98) = 10;   % Egr2 gene (ASSUMPTION ISSUE D) (0.587_ 
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Xind(99) = 10;      % MBP gene (73.5) 
Xind(100) = 4.72e3; % PKC (used PRKCA) 
Xind(101) = 10;  % YY1 gene (ASSUMPTION ISSUE D) (0.867) 
Xind(102) = 10;     % O4 gene (DATA NOT FOUND) 
Xind(103) = 10;     % O1 gene (DATA NOT FOUND) 
Xind(104) = 10;   % Cdk4 gene (ASSUMPTION ISSUE D) (0.97) 
Xind(105) = 10;  % p21 gene (ASSUMPTION ISSUE D) (1.416) 
Xind(106) = 10;  % p27 gene (ASSUMPTION ISSUE D) (1.086) 
Xind(107) = 10;   % PTEN gene (ASSUMPTION ISSUE D) (1.41) 
Xind(108) = 7.385;  % Smad1 
Xind(109) = 10;     % Sp1 (whole organism is 2.85e2) 
Xind(110) = 10;     % MPZ gene (ASSUMPTION ISSUE D) (95.3) 
Xind(111) = 10;     % ATP (PLACEHOLDER) 
Xind(112) = 7.39e1; % PDE4 (used PDE4A) 
Xind(113) = 10;     % PDE7 (whole organism is 4.50) 
Xind(114) = 10;     % MAG gene (ASSUMPTION ISSUE D) (20) 
Xind(115) = 10;     % PPARy bound (whole organism is 6.42) 
Xind(116) = 3.39e1; % cPLA2 
Xind(117) = 10;   % Sp5 gene (5.69) 
 
Xind(118) = 10 + A2;     % BIIB033 
Xind(119) = 10;  % BDNF gene (OPC) (ASSUMPTION ISSUE D) (0.842) 
Xind(120) = 10;   % ErB3 gene (0.59) 
Xind(121) = 1.16e2; % Lyn 
Xind(122) = 10;      % TNFa gene (OPC) (ASSUMPTION ISSUE D) (1) 
Xind(123) = D;      % Simvastatin 
Xind(124) = E;      % Lovastatin 
Xind(125) = 1e9;     % HMG-CoA (placeholder) (1e10) 
Xind(126) = 10;     % HMG-CoA reductase (placeholder, estimate was at 0.103) 
Xind(127) = 5.47e2; % Mevalonate kinase (5.47e2) 
Xind(128) = 2.42e3; % phosphomevalonate kinase 
Xind(129) = 1.39e3; % Mevalonate PP decarboxylase 
Xind(130) = 6.32e2; % farnesyl PP synthase 
Xind(131) = 4.70e2; % geranylgeranylPP synthase 
Xind(132) = 4.69e2; % Squalene synthase 
Xind(133) = 0.463;  % Smoothened 
Xind(134) = 10;     %NFkB/IkB complex (OPC) (sort of ASSUMPTION CODE C) 
Xind(135) = 10;  % HES5 gene (ASSUMPTION ISSUE D) (0.895) 
Xind(136) = K;      % rHIgM22 
Xind(137) = 8.37e-1;% avB3 integrin 
Xind(138) = W;      % GNbAC1 
Xind(139) = 10; %Adenosine neuron 
Xind(140) = 10; %UDP neuron 
 
 
 
 
 
 
 
% Write initial rates for flux equations. Any reaction that does not have 
% any promoters or inibitors is assigned a k value. Any reaction that has 
% promoters or inhibitors is assigned an X0 value and corresponding 
% differential equation. 
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%0.01 used as placeholder (especially for vague processes) 
%rates kept in nM/s/mg 
 
k(1) = 0.01;   % J1  k1 
k(2) = 0.01;   % J2  k2 
k(3) = 0.01;   % J3  k3 
k(4) = 0.01;   % J4  k4 
k(5) = 0.01;   % J5  k5 
k(6) = 0.01;   % J6  k6 
X0(1) = 0.01;   % J7  X1 
k(8) = 0.01;    % J8  k8 
X0(2) = 0.01;   % J9  X2 
X0(3) = 0.01;   % J10 X3 
X0(4) = 0.01;   % J11 X4 
X0(5) = 0.01;   % J12 X5 
X0(6) = 0.01;   % J13 X6 
X0(7) = 0.01;   % J14 X7 
X0(8) = 0.01;   % J15 X8 SABIO reference 4221 (REALLY REALLY FAST) (11.67) 
X0(9) = 0.01;   % J16 X9 
X0(10) = 0.01;  % J17 X10 
X0(11) = 0.01;  % J18 X11 
X0(12) = 0.01;  % J19 X12 
X0(13) = 0.01;  % J20 X13 
k(9) = 0.01;    % J21 k9 
k(10) = 0.01;   % J22 k10 
X0(14) = 0.01;  % J23 X14 
k(12) = 0.01;   % J24 k12 
k(13) = 0.01;   % J25 k13 
k(14) = 0.01;   % J26 k14 
k(15) = 0.01;   % J27 k15 
k(16) = 0.01;   % J28 k16 
k(17) = 0.01;   % J29 k17 
k(18) = 0.01;   % J30 k18 
X0(15) = 0.01;  % J31 X15 
k(11) = 0.01;   % J32 k11 
k(19) = 0.01;   % J33 k19 
k(20) = 0.01;   % J34 k20 
k(21) = 0.01;   % J35 k21 
k(22) = 0.0001;   % J36 k22 
X0(16) = 0.01;  % J37 X16 
X0(17) = 0.01;  % J38 X17 
X0(18) = 0.01;  % J39 X18 
k(23) = 0.01;   % J40 k23 
k(24) = 0.01;   % J41 k24 
X0(19) = 0.01;  % J42 X19 
X0(20) = 0.01;  % J43 X20 
X0(21) = 0.01;  % J44 X21 
X0(22) = 0.01;  % J45 X22 SABIO entry ID 3525 (REALLY REALLY SLOW 0.00002) 
k(25) = 0.01;   % J46 k25 
k(26) = 0.01;   % J47 k26 
k(27) = 0.01;   % J48 k27 
X0(23) = 0.01;  % J49 X23 
X0(24) = 0.01;  % J50 X24 
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X0(25) = 0.01;  % J51 X25 
X0(26) = 0.01;  % J52 X26 
k(28) = 0.01;   % J53 k28 
k(30) = 0.01;   % J54 k30 
X0(27) = 0.01;  % J55 X27 
X0(28) = 0.01;  % J56 X28 
X0(29) = 0.01;  % J57 X29 
X0(30) = 0.01;  % J58 X30 
X0(31) = 0.01;  % J59 X31 
k(31) = 0.01;   % J60 k31 
X0(32) = 0.01;  % J61 X32 
k(32) = 0.01;   % J62 k32 
X0(33) = 0.01;  % J63 X33 
X0(34) = 0.01;  % J64 X34 
X0(35) = 0.01;  % J65 X35 
X0(36) = 0.01;  % J66 X36 
k(33) = 0.01;   % J67 k33 
k(34) = 0.01;   % J68 k34 
X0(37) = 0.01;  % J69 X37 
X0(38) = 0.01;  % J70 X38 
X0(39) = 0.01;  % J71 X39 
k(35) = 0.01;   % J72 k35 
k(36) = 0.01;   % J73 k36 
k(37) = 0.01;   % J74 k37 
k(38) = 0.01;   % J75 k38 
k(39) = 0.01;   % J76 k39 
k(40) = 0.01;   % J77 k40 
k(41) = 0.01;   % J78 k41 
k(42) = 0.01;   % J79 k42 
k(89) = 0.01;   % J80 k89 
k(44) = 0.01;   % J81 k44 
k(45) = 0.01;   % J82 k45 
X0(40) = 0.01;  % J83 X40 
X0(41) = 0.01;  % J84 X41 
k(46) = 0.01;   % J85 k46 
k(47) = 0.01;   % J86 k47 
k(48) = 0.01;   % J87 k48 
X0(42) = 0.01;  % J88 X42 
k(49) = 0.01;   % J89 k49 
k(50) = 0.01;   % J90 k50 
X0(43) = 0.01;  % J91 X43 
X0(44) = 0.01;  % J92 X44 
k(51) = 0.01;   % J93 k51 
X0(45) = 0.01;  % J94 X45 
k(52) = 0.01;   % J95 k52 
X0(46) = 0.01;  % J96 X46 
k(53) = 0.01;   % J97 k53 
k(54) = 0.01;   % J98 k54 
k(55) = 0.01;   % J99 k55 
k(56) = 0.01;   % J100 k56 
X0(47) = 0.01;  % J101 X47 
k(57) = 0.01;   % J102 k57 
X0(48) = 0.01;  % J103 X48 
X0(49) = 0.01;  % J104 X49 
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X0(50) = 0.01;  % J105 X50 
k(58) = 0.01;   % J106 k58 
X0(51) = 0.01;  % J107 X51 
X0(52) = 0.01;  % J108 X52 
X0(53) = 0.01;  % J109 X53 
X0(54) = 0.01;  % J110 X54 
k(59) = 0.01;   % J111 k59 
X0(55) = 0.01;  % J112 X55 
k(60) = 0.01;   % J113 k60 
k(61) = 0.01;   % J114 k61 
k(43) = 0.01;   % J115 k43 
k(62) = 0.01;   % J116 k62 
X0(57) = 0.01;  % J117 X57 
X0(58) = 0.01;  % J118 X58 
X0(59) = 0.01;  % J119 X59 
X0(60) = 0.01;  % J120 X60 
X0(61) = 0.01;  % J121 X61 
X0(62) = 0.01;  % J122 X62 SABIO Reaction ID 2490 (0.275) 
X0(63) = 0.01;  % J123 X63 
X0(64) = 0.01;  % J124 X64 
X0(65) = 0.01;  % J125 X65 
X0(79) = 0.01;  % J126 X79 
k(64) = 0.01;   % J127 k64 
k(65) = 0.01;   % J128 k65 
X0(66) = 0.01;  % J129 X66 
X0(67) = 0.01;  % J130 X67 
X0(68) = 0.01;  % J131 X68 
X0(69) = 0.01;  % J132 X69 
X0(70) = 0.01;  % J133 X70 
X0(71) = 0.01;  % J134 X71 
k(87) = 0.01;   % J135 k87 
k(67) = 0.01;   % J136 k67 
k(68) = 0.01;   % J137 k68 
k(69) = 0.01;   % J138 k69 
k(70) = 0.01;   % J139 k70 
X0(72) = 0.01;  % J140 X72 
X0(73) = 0.01;  % J141 X73 
X0(74) = 0.01;  % J142 X74 
k(71) = 0.01;   % J143 k71 
X0(76) = 0.01;  % J145 X76 
X0(75) = 0.01;  % J144 X75 
X0(77) = 0.01;  % J146 X77 
X0(78) = 0.01;  % J147 X78 
k(72) = 0.01;   % J148 k72 
k(73) = 0.01;   % J149 k73 
k(74) = 0.01;   % J150 k74 
k(63) = 0.01;   % J151 k63 
k(75) = 0.01;   % J152 k75 
X0(80) = 0.0021;  % J153 X80 SABIO Reaction ID 101 
X0(81) = 0.0346;  % J154 X81 SABIO Reaction ID 292 averaged 
k(76) = 0.01;   % J155 k76 
X0(82) = 0.01;  % J156 X82 
X0(83) = 0.01;  % J157 X83 
X0(84) = 0.01;  % J158 X84 
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X0(85) = 0.01;  % J159 X85 
X0(86) = 0.01;  % J160 X86 
X0(87) = 0.01; % J161 X87 SABIO Reaction ID 6923 (THIS SEEMS REALLY REALLY FAST 493.3) 
X0(88) = 0.01; % J162 X88 SABIO Reaction ID 6922(REALLY REALLY FAST 616.7) 
X0(89) = 0.02067; % J163 X89 SABIO Reaction ID 3066 
X0(90) = 0.01; % J164 X90 SABIO reaction ID 1380 (REALLY REALLY SLOW 0.00001867) 
X0(91) = 0.0045; % J165 X91 SABIO reaction ID 2041 
X0(92) = 0.01; % J166 X92 SABIO Reaction ID 2078 (REALLY REALLY FAST 211.67) 
X0(93) = 0.01; % J167 X93 SABIO REaction ID 5806 (REALLY REALLY FAST 75) 
k(78) = 0.01;   % J168 k78 
k(79) = 0.01;   % J169 k79 
X0(94) = 0.01;   % J170 X94 
X0(95) = 0.01;   % J171 X95 
X0(96) = 0.01;   % J172 X96 
X0(97) = 0.01;   % J173 X97 
k(80) = 0.01;   % J174 k80 
k(81) = 0.01;   % J175 k81 
X0(98) = 0.01;   % J176 X98 
X0(99) = 0.01;   % J177 X99 
X0(100) = 0.01;  % J178 X100 
X0(101) = 0.01;  % J179 X101 
X0(102) = 0.01;  % J180 X102 
X0(103) = 0.01;  % J181 X103 
X0(104) = 0.01;  % J182 X104 
X0(105) = 0.01;  % J183 X105 
k(83) = 0.01;    % J184 k83 
k(82) = 0.01;    % J185 k82 
k(85) = 0.01;    % J186 k85 
k(86) = 0.01;    % J187 k86 
X0(125) = 0.01;   % J188 X125 
k(88) = 0.01;    % J189 k88 
X0(56) = 0.01;   % J190 X56 
k(90) = 0.01;    % J191 k90 
k(91) = 0.01;    % J192 k91 
X0(121) = 0.01;  % J193 X121 
k(7) = 0.01;     % J194 k7 
k(29) = 0.01;    % J195 k29 
k(84) = 0.01;    % J196 k84 
X0(106) = 0.01;  % J197 X106 
X0(107) = 0.01;  % J198 X107 
X0(108) = 0.01;  % J199 X108 
X0(109) = 0.01;  % J200 X109 
X0(110) = 0.01;  % J201 X110 
X0(111) = 0.01;  % J202 X111 
X0(112) = 0.01;  % J203 X112 
k(92) = 0.01;    % J204 k92 
X0(113) = 0.01;  % J205 X113 
X0(114) = 0.01;   % J206 X114 
k(93) = 0.01;    % J207 k93 
X0(115) = 0.01;  % J208 X115 
k(95) = 0.01;    % J209 k95 
X0(116) = 0.01;  % J210 X116 
X0(117) = 0.01;  % J211 X117 
k(96) = 0.01;    % J212 k96 
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X0(127) = 0.01;  % J213 X127 
k(97) = 0.01;    % J214 k97 
X0(118) = 0.01;  % J215 X118 
X0(120) = 0.01;  % J216 X120 
X0(122) = 0.01;  % J217 X122 
X0(123) = 0.01;  % J218 X123 
X0(124) = 0.01;  % J219 X124 
k(94) = 0.01;    % J220 k94 
X0(126) = 0.01;  % J221 X126 
X0(128) = 0.01;  % J222 X128 
X0(129) = 0.01;  % J223 X129 
X0(130) = 0.01;  % J224 X130 
X0(131) = 0.01;  % J225 X131 
k(79) = 0.01;    % J226 k79 
X0(133) = 0.001;  % J227 X133 
X0(134) = 0.01;  % J228 X134 
X0(132) = 0.01; % J229 X132 
X0(119) = 0.01;  % J230 X119 
k(98) = 0.01;    % J231 k98 
k(99) = 0.01;    % J232 k99 
k(100) = 0.01;   % J233 k100 
k(101) = 0.01;   % J234 k101 
k(102) = 0.01;   % J235 k102 
k(103) = 0.01;   % J236 k103 
k(104) = 0.01;   % J237 k104 
k(105) = 0.01;   % J238 k105 
k(106) = 0.01;   % J239 k106 
k(107) = 0.01;   % J240 k107 
k(108) = 0.01;   % J241 k108 
k(109) = 0.01;   % J242 k109 
k(110) = 0.01;   % J243 k110 
k(111) = 0.01;   % J244 k111 
k(112) = 0.01;   % J245 k112 
k(113) = 0.01;   % J246 k113 
k(114) = 0.01;   % J247 k114 
k(115) = 0.01;   % J248 k115 
k(116) = 0.01;   % J249 k116 
k(117) = 0.01;   % J250 k117 
k(118) = 0.01;   % J251 k118 
k(119) = 0.01;   % J252 k119 
k(120) = 0.01;   % J253 k120 
k(121) = 0.01;   % J254 k121 
k(122) = 0.01;   % J255 k122 
k(123) = 0.01;   % J256 k123 
k(124) = 0.01;   % J257 k124 
k(125) = 0.01;   % J258 k125 
k(126) = 0.01;   % J259 k126 
k(127) = 0.01;   % J260 k127 
k(128) = 0.01;   % J261 k128 
k(129) = 0.01;   % J262 k129 
k(130) = 0.01;   % J263 k130 
k(131) = 0.01;   % J264 k131 
k(132) = 0.01;   % J265 k132 
k(133) = 0.01;   % J266 k133 
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k(134) = 0.01;   % J267 k134 
k(135) = 0.01;   % J268 k135 
k(136) = 0.01;   % J269 k136 
k(137) = 0.01;   % J270 k137 
k(139) = 0.01;   % J271 k139 
k(66) = 0.01;   % J272 k66 
k(140) = 0.01;   % J273 k140 
k(141) = 0.01;   % J274 k141 
k(142) = 0.01;   % J275 k142 
k(143) = 0.01;   % J276 k143 
k(144) = 0.01;   % J277 k144 (0.01) 
k(145) = 0.01;   % J278 k145 (0.01) 
k(146) = 0.01;   % J279 k146 
k(147) = 0.01;   % J280 k147 
k(148) = 0.01;   % J281 k148 (0.01) 
X0(406) = 0.01; 
X0(409) = 0.01; 
k(149) = 0.01; 
k(150) = 0.01; 
k(151) = 0.01; 
k(152) = 0.01; 
k(153) = 0.01; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% Create initiatl output array of zeros containing as many entries as 
% dependent variables. 
dx = zeros(404,1); 
% Systems equations consist of flux equations for the reactions increasing 
% the species concentration minus the flux equations for reactions 
% decreasing the species concentration. Each dependent variable receives a 
% systems equation. 
% RATE EQUATIONS 
dx(1) = 0.01 * (X(142) + X(146)); 
dx(2) = 0.01 * Xind(26); 
dx(3) = 0.01 * Xind(1); 
dx(4) = 0.01 * Xind(1); 
dx(5) = 0.01 * (Xind(1) + X(145)); 
dx(6) = 0.01 * Xind(1); 
dx(7) = 0.01 * X(144); 
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dx(8) = 0.01 * X(150); 
dx(9) = 0.01 * X(151); 
dx(10) = 0.01 * X(155); 
dx(11) = 0.01 * X(152); 
dx(12) = 0.01 * X(153); 
dx(13) = 0.01 * X(153); 
dx(14) = 0.01 * -X(163); 
dx(15) = 0.01 * -Xind(64); 
dx(16) = 0.01 * Xind(1); 
dx(17) = 0.01 * Xind(1); 
dx(18) = 0.01 * Xind(1); 
dx(19) = 0.01 * Xind(1); 
dx(20) = 0.01 * X(164); 
dx(21) = 0.01 * (X(179) + X(180)); 
dx(22) = 0.01 * (X(166) + X(167)); 
dx(23) = 0.01 * (X(140) + X(141)); 
dx(24) = 0.01 * Xind(42); 
dx(25) = 0.01 * Xind(42); 
dx(26) = 0.01 * Xind(42); 
dx(27) = 0.01 * (X(161) + X(175) + X(162) + X(229) + Xind(84) + X(221) + X(191) + 
X(212)); 
dx(28) = 0.01 * (X(175) + X(161) + X(162) + X(177) + Xind(23) + X(229) + X(332)); 
dx(29) = 0.01 * X(228); 
dx(30) = 0.01 * X(193); 
dx(31) = 0.01 * (X(162) + X(161) + X(175) + X(258) + X(200) + X(211) + X(230) + X(293) 
+ X(294) + X(321) - X(264)); 
dx(32) = 0.01 * X(187); 
dx(33) = 0.01 * X(178); 
dx(34) = 0.01 * X(180); 
dx(35) = 0.01 * X(168); 
dx(36) = 0.01 * X(196); 
dx(37) = 0.01 * X(322); 
dx(38) = 0.01 * (X(187) + X(199)); 
dx(39) = 0.01 * Xind(27); 
dx(40) = 0.01 * X(139); 
dx(41) = 0.01 * X(202); 
dx(42) = 0.01 * X(194); 
dx(43) = 0.01 * X(205); 
dx(44) = 0.01 * Xind(42); 
dx(45) = 0.01 * (X(211) + X(206) + X(177) + X(357) + X(274) + X(275) + X(322) + X(333) 
- X(256)); 
dx(46) = 0.01 * X(145); 
dx(47) = 0.01 * (X(261) + Xind(83) - X(215)); 
dx(48) = 0.01 * X(217); 
dx(49) = 0.01 * X(212); 
dx(50) = 0.01 * (X(250) + X(387)); 
dx(51) = 0.01 * X(186); 
dx(52) = 0.01 * (Xind(75) - X(207)); 
dx(53) = 0.01 * (X(225) - X(297)); 
dx(54) = 0.01 * X(187); 
dx(55) = 0.01 * -X(265); 
dx(56) = 0.01 * X(296); 
dx(57) = 0.01 * X(190); 
dx(58) = 0.01 * (X(190) + X(191) + X(215)); 
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dx(59) = 0.01 * (Xind(83) + Xind(92) - Xind(84) + Xind(22)); 
dx(60) = 0.01 * -X(363); 
dx(61) = 0.01 * (X(186) + X(219)); 
dx(62) = 0.01 * (X(235) + X(249) + Xind(88) - Xind(89)); 
dx(63) = 0.01 * X(187); 
dx(64) = 0.01 * Xind(56); 
dx(65) = 0.01 * X(238); 
dx(66) = 0.01 * X(186); 
dx(67) = 0.01 * (X(249) + X(186) + X(231)); 
dx(68) = 0.01 * Xind(1); 
dx(69) = 0.01 * -X(216); 
dx(70) = 0.01 * (X(234) + X(327) - X(363)); 
dx(71) = 0.01 * (X(250) - X(363)); 
dx(72) = 0.01 * (X(248) + X(258) + X(200) + X(293) + X(294) + X(297) + Xind(100)); 
dx(73) = 0.01 * -X(68); 
dx(74) = 0.01 * X(190); 
dx(75) = 0.01 * X(186); 
dx(76) = 0.01 * X(253); 
dx(77) = 0.01 * X(253); 
dx(78) = 0.01 * X(262); 
dx(79) = 0.01 * X(265); 
dx(80) = 0.01 * (X(286) - X(291) - X(292)); 
dx(81) = 0.01 * (Xind(112) + Xind(113)); 
dx(82) = 0.01 * (X(263) - X(264)); 
dx(83) = 0.01 * X(190); 
dx(84) = 0.01 * X(272); 
dx(85) = 0.01 * -Xind(118); 
dx(86) = 0.01 * X(277); 
dx(87) = 0.01 * (Xind(126) - Xind(123) - Xind(124)); 
dx(88) = 0.01 * Xind(127); 
dx(89) = 0.01 * Xind(128); 
dx(90) = 0.01 * Xind(129); 
dx(91) = 0.01 * Xind(130); 
dx(92) = 0.01 * Xind(131); 
dx(93) = 0.01 * Xind(132); 
dx(94) = 0.01 * X(202); 
dx(95) = 0.01 * X(279); 
dx(96) = 0.01 * -Xind(138); 
dx(97) = 0.01 * (X(281) + X(282)); 
dx(98) = 0.01 * (-X(289) - X(290) - X(292)); 
dx(99) = 0.01 * (-X(289) - X(290) - X(292)); 
dx(100) = 0.01 * (X(289) + X(290) + X(292)); 
dx(101) = 0.01 * (X(289) - X(412)); 
dx(102) = 0.01 * (X(289) + X(290) + X(292) + X(255) + X(194) + X(246) + X(160) + 
X(298) + X(254) + X(312) + Xind(82) + Xind (86) + Xind(80) + X(210) + X(306) - X(310) 
- X(302) - X(299)); 
dx(103) = 0.01 * (X(289) + X(290) + X(292)); 
dx(104) = 0.01 * -Xind(43); 
dx(105) = 0.01 * -Xind(43); 
dx(106) = 0.01 * (X(386) - X(300)); 
dx(107) = 0.01 * X(216); 
dx(108) = 0.01 * (X(160) + X(298)); 
dx(109) = 0.01 * (X(309) - X(308)); 
dx(110) = 0.01 * X(160); 
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dx(111) = 0.01 * X(249); 
dx(112) = 0.01 * (X(190) + X(235)); 
dx(113) = 0.01 * (X(235) + X(186) + X(231)); 
dx(114) = 0.01 * (X(311) - X(328) - X(245) - Xind(24)); 
dx(115) = 0.01 * X(313); 
dx(116) = 0.01 * (X(160) + X(298) + X(312)); 
dx(117) = 0.01 * (X(309) - X(308)); 
dx(118) = 0.01 * (X(177) + Xind(95) + Xind(96) + X(331)); 
dx(119) = 0.01 * X(187); 
dx(120) = 0.01 * Xind(83); 
dx(121) = 0.01 * (X(185) + X(189) + X(158) + X(200) + X(204) + X(257)); 
dx(122) = 0.01 * X(323); 
dx(123) = 0.01 * X(182); 
dx(124) = 0.01 * (X(165) + X(177) + Xind(55) + X(182) + X(297) - X(408)); %OPC 
Proliferation 
dx(125) = 0.01 * Xind(45); 
dx(126) = 0.01 * X(333); 
dx(127) = 0.01 * (X(181) + X(304) + X(305) + X(315) + X(316) + X(325) + X(329) + 
X(273) - X(198)); 
dx(128) = 0.01 * (Xind(68) + X(326) + X(309) - Xind(67) - Xind(69)); 
dx(129) = 0.01 * X(249); 
dx(130) = 0.01 * Xind(59); 
dx(131) = 0.01 * X(245); 
dx(132) = 0.01 * (X(358) + X(241) + X(197)); 
dx(133) = 0.01 * X(160); 
dx(134) = 0.01 * (X(250) + X(234) + X(298) + X(160) + Xind(40) + Xind(82) + X(387) - 
Xind(41) - Xind(32)); 
dx(405) = 0.01 * Xind(1); 
dx(409) = 0.01 * Xind(1); 
 
 
 
 
% SYSTEMS EQUATIONS, Currently everything pointing toward OPC 
% Differentiation has had it's subtracted statement deleted 
dx(135) = k(89) * X(332) - k(98) * X(135) * X(173); 
dx(136) = k(90) * X(333) - k(99) * X(136) * X(220); 
dx(137) = X(39) * X(201) + k(101) * X(158) + k(103) * X(170) - k(9) * X(137) - k(22) * 
X(137); 
dx(138) = Xind(1) * k(2) + X(86) * Xind(122) + k(39) * X(144) + k(73) * X(168) - k(8) 
* X(138) * X(337) - k(20) * X(138) * X(343); 
dx(139) = Xind(1) * k(3); 
dx(140) = Xind(1) * k(4); 
dx(141) = Xind(1) * k(5); 
dx(142) = X(352) * X(353) * k(6) - k(107) * X(142); 
dx(143) = X(1) * Xind(4) + k(112) * X(202) - X(143) * X(288) * k(40); 
dx(144) = k(8) * X(138) * X(337) - k(39) * X(144); 
dx(145) = X(2) * Xind(6) + k(100) * X(167) - k(19) * X(145) * X(342); 
dx(146) = X(3) * Xind(7); 
dx(147) = X(4) * Xind(8) + k(26) * X(162) - k(15) * X(147) * X(243); 
dx(148) = X(5) * Xind(9) + k(38) * X(163)- k(16) * X(148) * X(214); 
dx(149) = X(6) * Xind(10) + k(72) * X(164) - k(17) * X(149) * X(285); 
dx(150) = X(7) * Xind(11); 
dx(151) = X(8) * Xind(12); 
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dx(152) = X(9) * X(404) - k(33) * X(152); 
dx(153) = X(10) * Xind(14); 
dx(154) = X(10) * Xind(14) - k(12) * X(154); 
dx(155) = X(11) * X(247) - k(148) * X(155); 
dx(156) = X(12) * Xind(16) - k(18) * X(156) * X(338) + k(50) * X(165); 
dx(157) = X(13) * Xind(17) + k(30) * X(166) - k(11) * X(157) * X(342); 
dx(158) = k(9) * X(137) * X(344) - k(101) * X(158); 
dx(159) = X(124) * Xind(18); %OPC Proliferation 
dx(160) = k(65) * X(194) + k(64) * X(195) + k(69) * X(251) + k(68) * X(252) + X(14) * 
X(177) + k(13) * X(165) + X(15) * X(223) + k(54) * X(213) + k(43) * X(235) + k(62) * 
X(234) + k(61) * X(242) + k(36) * X(182) + k(44) * X(227) + k(45) * X(209) - k(41) * 
X(204) - k(42) * Xind(55) - k(37) * X(297) - k(35) * X(170) - k(67) * X(240) - k(27) * 
X(159) - k(55) * X(216) - k(91) * X(277) - k(63) * X(276) + k(151) * X(408); %OPC 
Differentiation 
dx(161) = k(14) * X(171) * X(243) - k(108) * X(161); 
dx(162) = k(15) * X(147) * X(243) - k(26) * X(162); 
dx(163) = k(16) * X(148) * X(214) - k(38) * X(163); 
dx(164) = k(17) * X(149) * X(285) + k(17) * X(183) * X(285) - k(72) * X(164); 
dx(165) = k(18) * X(156) * X(338) - k(50) * X(165); 
dx(166) = k(11) * X(342) * X(157) - k(30) * X(166); 
dx(167) = k(19) * X(342) * X(145) - k(100) * X(167); 
dx(168) = k(20) * X(138) * X(343) - k(73) * X(168); 
dx(169) = k(21) * X(345) * X(346) + k(103) * X(170) - k(102) * X(169); 
dx(170) = k(22) * X(169) * X(137) - k(103) * X(170); 
dx(171) = X(16) * X(29) + k(34) * X(174) + k(108) * X(161) + k(26) * X(162) + k(47) * 
X(175) - k(60) * X(171) * X(365) - k(23) * X(169) * X(339) - k(14) * X(171) * X(243); 
dx(172) = X(18) * Xind(31) - k(46) * X(172) * X(288); 
dx(173) = X(17) * Xind(30) + k(89) * X(332) - k(98) * X(173) * X(26); 
dx(174) = k(23) * X(171) * X(339) - k(34) * X(174); 
dx(175) = k(24) * X(243) * X(176) - k(47) * X(175); 
dx(176) = X(19) * X(33) + k(47) * X(175) - k(24) * X(243) * X(176); 
dx(177) = X(20) * X(285); 
dx(178) = X(21) * X(342); 
dx(179) = X(22) * Xind(34); 
dx(180) = k(25) * Xind(35) * Xind(36); 
dx(181) = X(121) * Xind(2); 
dx(182) = X(23) * Xind(37); 
dx(183) = Xind(38) * X(24) + k(72) * X(164) - k(17) * X(285) * X(183); 
dx(184) = k(109) * X(229) + X(25) * Xind(39) -X(55) * X(184) *  X(354); 
dx(185) = X(26) * X(341) * X(340) - k(28) * X(185); 
dx(186) = X(27) * X(396) - k(140) * X(186); 
dx(187) = X(28) * X(188) - X(29) * X(187); 
dx(188) = X(29) * X(187) - X(28) * X(188); 
dx(189) = X(30) * Xind(44); 
dx(190) = X(31) * X(397) - k(145) * X(190); 
dx(191) = k(31) * X(355) * X(192) - k(110) * X(191); 
dx(192) = X(32) * Xind(47) + k(110) * X(191) + k(111) * X(193) - k(31) * X(355) * 
X(192) - k(32) * X(192) * X(356); 
dx(193) = k(32) * X(192) * X(356) - k(111) * X(193); 
dx(194) = X(33) * Xind(49); 
dx(195) = X(34) * Xind(50); 
dx(196) = X(35) * Xind(51); 
dx(197) = X(36) * Xind(52); 
dx(198) = X(132) * Xind(3); 
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dx(199) = X(37) * Xind(53); 
dx(200) = X(38) * Xind(54); 
dx(201) = k(1) * Xind(1); 
dx(202) = k(40) * X(143) * X(288) - k(112) * X(202); 
dx(203) = X(40) * Xind(56); 
dx(204) = X(41) * Xind(57); 
dx(205) = k(46) * X(172) * X(288) - k(113) * X(205); 
dx(206) = k(48) * X(357) * X(222) - k(114) * X(206); 
dx(207) = X(42) * Xind(60) + k(115) * X(208) - k(49) * X(207) * X(358); 
dx(208) = k(49) * X(207) * X(358) - k(115) * X(208); 
dx(209) = X(43) * Xind(61); 
dx(210) = X(44) * Xind(62) + k(116) * X(211) - k(51) * X(210) * X(266); 
dx(211) = k(51) * X(210) * X(266) - k(116) * X(211); 
dx(212) = X(45) * X(398) - k(141) * X(212); 
dx(213) = k(52) * X(360) * X(280) - k(117) * X(213); 
dx(214) = k(38) * X(163) + X(46) * Xind(65) - k(16) * X(148) * X(214); 
dx(215) = k(53) * X(361) * X(362) - k(118) * X(215); 
dx(216) = k(56) * X(363) * X(364) - k(119) * X(216); 
dx(217) = X(47) * Xind(70); 
dx(218) = k(57) * X(219) - X(48) * X(218); 
dx(219) = X(48) * X(218) - k(57) * X(219); 
dx(220) = k(90) * X(333) - k(99) * X(220) * X(136); 
dx(221) = X(49) * X(399) - k(142) * X(221); 
dx(222) = X(50) * Xind(72) + k(114) * X(206) - k(48) * X(222) * X(357); 
dx(223) = k(58) * Xind(21); 
dx(224) = X(51) * X(221); 
dx(225) = X(52) * Xind(74); 
dx(226) = X(53) * Xind(76) - X(66) * X(226); 
dx(227) = X(54) * Xind(77); 
dx(228) = k(59) * X(349) * X(350) - k(105) * X(228); 
dx(229) = X(55) * X(184) * X(354) + X(55) * X(301) * X(354) - k(109) * X(229); 
dx(230) = k(60) * X(171) * X(365) - k(120) * X(230); 
dx(231) = X(57) * X(401) - k(144) * X(231); 
dx(232) = X(58) * Xind(83); 
dx(233) = X(59) * X(363); 
dx(234) = X(60) * Xind(85); 
dx(235) = X(61) * X(402) - k(143) * X(235); 
dx(236) = X(62) * Xind(87); 
dx(237) = X(64) * X(238) - X(63) * X(237); 
dx(238) = X(63) * X(237) - X(64) * X(238); 
dx(239) = X(65) * X(240) - X(79) * X(239); 
dx(240) = X(79) * X(239) + k(124) * X(264) - X(65) * X(240) - X(84) * X(240) * X(370); 
dx(241) = X(66) * X(226); 
dx(242) = X(67) * Xind(90); 
dx(243) = X(68) * Xind(91) + k(121) * X(257) + k(108) * X(161) + k(26) * X(162) + 
k(47) * X(175) - k(24) * X(243) * X(176) - k(14) * X(243) * X(171) - k(15) * X(243) * 
X(147) - k(74) * X(243) * X(359) * X(366); 
dx(244) = X(69) * Xind(92); 
dx(245) = X(70) * Xind(93); 
dx(246) = X(71) * Xind(94); 
dx(247) = k(148) * X(155) - X(11) * X(247); 
dx(248) = k(70) * X(367) * X(368) - k(122) * X(248); 
dx(249) = X(72) * X(400) - k(146) * X(249); 
dx(250) = X(73) * Xind(101); 
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dx(251) = X(74) * Xind(102); 
dx(252) = k(71) * Xind(103); 
dx(253) = X(75) * Xind(104); 
dx(254) = X(76) * Xind(105); 
dx(255) = X(77) * Xind(106); 
dx(256) = X(78) * Xind(107); 
dx(257) = k(74) * X(366) * X(359) * X(243) - k(121) * X(257); 
dx(258) = k(75) * X(351) * X(259) - k(106) * X(258); 
dx(259) = X(80) * Xind(111) + k(106) * X(258) - k(75) * X(259) * X(351); 
dx(260) = k(123) * X(261) + X(81) * X(259) - k(76) * X(260) * X(369); 
dx(261) = k(76) * X(260) * X(369) - k(123) * X(261); 
dx(262) = X(82) * Xind(115); 
dx(263) = X(83) * Xind(116); 
dx(264) = X(84) * X(240) * X(370) - k(124) * X(264); 
dx(265) = X(85) * X(371) * X(372) - k(125) * X(265); 
dx(266) = k(116) * X(211) - k(51) * X(266) * X(210); 
dx(267) = X(87) * Xind(125) - X(88) * X(267); 
dx(268) = X(88) * X(267) - X(89) * X(268); 
dx(269) = X(89) * X(268) - X(90) * X(269); 
dx(270) = X(90) * X(269) - X(91) * X(270); 
dx(271) = X(91) * X(270) - X(93) * X(271) - X(92) * X(271); 
dx(272) = X(92) * X(271); 
dx(273) = X(93) * X(271); 
dx(274) = k(78) * X(374) * X(283) - k(126) * X(274); 
dx(275) = k(77) * X(374) * X(284) - k(127) * X(275); 
dx(276) = X(94) * Xind(135); 
dx(277) = X(95) * Xind(134); 
dx(278) = X(95) * Xind(134) - k(10) * X(278); 
dx(279) = X(96) * X(375) * X(376) - k(128) * X(279); 
dx(280) = X(97) * Xind(79) + k(117) * X(213) - k(52) * X(280) * X(360); 
dx(281) = k(80) * Xind(78) * Xind(133); 
dx(282) = k(81) * Xind(28) * Xind(133); 
dx(283) = X(98) * Xind(120) + k(126) * X(274) - k(78) * X(283) * X(374); 
dx(284) = X(99) * Xind(15) + k(127) * X(275) - k(77) * X(284) * X(374); 
dx(285) = X(100) * Xind(19) + k(72) * X(164) - k(17) * X(285) * X(185) - k(17) * 
X(285) * X(149); 
dx(286) = X(101) * Xind(13); 
dx(287) = X(102) * Xind(99) - X(118) * X(287); 
dx(288) = X(103) * Xind(71) + k(112) * X(202) + k(113) * X(205) - k(40) * X(288) * 
X(143) - k(46) * X(288) * X(172); 
dx(289) = X(104) * X(377) * X(381) - k(129) * X(289); 
dx(290) = X(105) * X(378) * X(381) - k(130) * X(290); 
dx(291) = k(83) * X(381) * X(379) - k(131) * X(291); 
dx(292) = k(82) * X(381) * X(380) - k(132) * X(292); 
dx(293) = k(85) * X(382) * X(383) - k(133) * X(293); 
dx(294) = k(86) * X(383) * X(295); 
dx(295) = X(125) * Xind(63); 
dx(296) = k(88) * Xind(136) * Xind(137); 
dx(297) = X(56) * Xind(121); 
dx(298) = k(7) * X(246); 
dx(299) = k(29) * X(384) * X(385) * X(387) - k(135) * X(300); 
dx(300) = k(84) * X(384) * X(385) * X(386) - k(134) * X(299); 
dx(301) = X(106) * Xind(119) + k(109) * X(229) - X(55) * X(301) * X(354); 
dx(302) = X(107) * Xind(117); 
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dx(303) = X(108) * Xind(114) - 0.5 * X(109) * X(303); 
dx(304) = X(109) * X(303); 
dx(305) = X(110) * Xind(110); 
dx(306) = X(111) * Xind(109); 
dx(307) = X(112) * X(388); 
dx(308) = k(92) * X(388) * X(389) - k(136) * X(308); 
dx(309) = X(113) * X(389); 
dx(310) = X(114) * X(390) * X(391) - k(137) * X(310); 
dx(311) = k(93) * Xind(108); 
dx(312) = X(115) * Xind(98); 
dx(313) = k(95) * X(392) * X(393) - k(138) * X(313); 
dx(314) = X(116) * Xind(97) - 0.5 * X(117) * X(314); 
dx(315) = X(117) * X(314); 
dx(316) = k(96) * X(330); 
dx(317) = X(131) * Xind(58) + k(139) * X(328) - k(79) * X(394) * X(317); 
dx(318) = k(97) * X(320) * X(327) - k(66) * X(318); 
dx(319) = X(118) * X(287) - 0.5 * X(128) * X(319); 
dx(320) = X(120) * Xind(81) + k(66) * X(318) - k(97) * X(320) * X(327); 
dx(321) = X(122) * X(403) - k(147) * X(321); 
dx(322) = X(123) * X(347) * X(348) - k(104) * X(322); 
dx(323) = k(94) * X(395) * X(324) - k(87) * X(323); 
dx(324) = X(126) * Xind(73) + k(87) * X(323) - k(94) * X(395) * X(324); 
dx(325) = X(128) * X(319); 
dx(326) = X(129) * Xind(66); 
dx(327) = X(130) * Xind(20) + k(66) * X(318) - k(97) * X(320) * X(327); 
dx(328) = k(79) * X(394) * X(317) - k(139) * X(328); 
dx(329) = X(133) * Xind(48); 
dx(330) = X(134) * Xind(46) - 0.5 * k(96) * X(330); 
dx(331) = X(135) * Xind(67); 
dx(332) = k(98) * X(173) * X(135) - k(89) * X(332); 
dx(333) = k(99) * X(136) * X(220) - k(90) * X(333); 
dx(334) = X(127) * Xind(25); 
dx(335) = k(12) * X(154); 
dx(336) = k(10) * X(278); 
dx(337) = k(39) * X(144) - k(8) * X(337) * X(138); 
dx(338) = k(50) * X(165) - k(18) * X(338) * X(156); 
dx(339) = k(34) * X(174) - k(23) * X(339) * X(171); 
dx(340) = k(28) * X(185) - X(26) * X(340) * X(341); 
dx(341) = k(28) * X(185) - X(26) * X(340) * X(341); 
dx(342) = k(30) * X(166) + k(100) * X(167) - k(11) * X(342) * X(157) - k(19) * X(342) 
* X(145) - X(21) * X(342); 
dx(343) = k(73) * X(168) - k(20) * X(343) * X(138); 
dx(344) = k(101) * X(158) - k(9) * X(344) * X(137); 
dx(345) = k(102) * X(169) - k(21) * X(345) * X(346); 
dx(346) = k(102) * X(169) - k(21) * X(345) * X(346); 
dx(347) = k(104) * X(322) - X(123) * X(347) * X(348); 
dx(348) = k(104) * X(322) - X(123) * X(347) * X(348); 
dx(349) = k(105) * X(228) - k(59) * X(349) * X(350); 
dx(350) = k(105) * X(228) - k(59) * X(349) * X(350); 
dx(351) = k(106) * X(258) - k(75) * X(351) * X(259); 
dx(352) = k(107) * X(142) - k(6) * X(352) * X(353); 
dx(353) = k(107) * X(142) - k(6) * X(352) * X(353); 
dx(354) = k(109) * X(229) - X(55) * X(184) * X(354) - X(55) * X(301) * X(354); 
dx(355) = k(110) * X(191) - k(31) * X(355) * X(192); 
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dx(356) = k(111) * X(193) - k(32) * X(192) * X(356); 
dx(357) = k(114) * X(206) - k(48) * X(222) * X(357); 
dx(358) = k(115) * X(208) - k(49) * X(207) * X(358) - X(51) * X(358); 
dx(359) = k(121) * X(257) - k(74) * X(366) * X(359) * X(243); 
dx(360) = k(117) * X(213) - k(52) * X(360) * X(280); 
dx(361) = k(118) * X(215) - k(53) * X(361) * X(362); 
dx(362) = k(118) * X(215) - k(53) * X(361) * X(362); 
dx(363) = k(119) * X(216) - k(56) * X(363) * X(364) - k(56) * Xind(22) * X(363) + 
k(56) * Xind(84) * X(363); 
dx(364) = k(119) * X(216) - k(56) * X(363) * X(364); 
dx(365) = k(120) * X(230) - k(60) * X(171) * X(365); 
dx(366) = k(121) * X(257) - k(74) * X(366) * X(359) * X(243); 
dx(367) = k(122) * X(248) - k(70) * X(367) * X(368); 
dx(368) = k(122) * X(248) - k(70) * X(367) * X(368); 
dx(369) = k(123) * X(261) - k(76) * X(260) * X(369); 
dx(370) = k(124) * X(264) - X(84) * X(240) * X(370); 
dx(371) = k(125) * X(265) - X(85) * X(372) * X(371); 
dx(372) = k(125) * X(265) - X(85) * X(372) * X(371); 
dx(373) = 0; 
dx(374) = k(126) * X(274) + k(127) * X(275) - k(77) * X(374) * X(284) - k(78) * X(374) 
* X(283); 
dx(375) = k(128) * X(279) - X(96) * X(375) * X(376); 
dx(376) = k(128) * X(279) - X(96) * X(375) * X(376); 
dx(377) = k(129) * X(289) - X(104) * X(381) * X(377); 
dx(378) = k(130) * X(290) - X(105) * X(378) * X(381); 
dx(379) = k(131) * X(291) - k(83) * X(379) * X(381); 
dx(380) = k(132) * X(292) - k(82) * X(380) * X(381); 
dx(381) = k(129) * X(289) + k(130) * X(290) + k(131) * X(291) + k(132) * X(292) - 
X(104) * X(381) * X(377) - X(105) * X(378) * X(381) - k(83) * X(379) * X(381) - k(82) 
* X(380) * X(381); 
dx(382) = k(133) * X(293) - k(85) * X(382) * X(383); 
dx(383) = k(133) * X(293) - k(85) * X(382) * X(383); 
dx(384) = k(134) * X(300) + k(135) * X(299) - k(84) * X(385) * X(384) * X(386) - k(29) 
* X(384) * X(387) * X(385); 
dx(385) = k(134) * X(300) + k(135) * X(299) - k(84) * X(385) * X(384) * X(386) - k(29) 
* X(384) * X(387) * X(385); 
dx(386) = k(134) * X(300) - k(84) * X(385) * X(384) * X(386); 
dx(387) = k(135) * X(299) - k(29) * X(384) * X(387) * X(385); 
dx(388) = k(136) * X(308) - k(92) * X(389) * X(388) - X(112) * X(388); 
dx(389) = k(136) * X(308) - k(92) * X(389) * X(388) - X(113) * X(389); 
dx(390) = k(137) * X(310) - X(114) * X(390) * X(391); 
dx(391) = k(137) * X(310) - X(114) * X(390) * X(391); 
dx(392) = k(138) * X(313) - k(95) * X(392) * X(393); 
dx(393) = k(138) * X(313) - k(95) * X(392) * X(393); 
dx(394) = k(139) * X(328) - k(79) * X(394) * X(317); 
dx(395) = k(87) * X(323) - k(94) * X(395) * X(324); 
dx(396) = k(140) * X(186) - X(27) * X(396); 
dx(397) = k(145) * X(190) - X(31) * X(397); 
dx(398) = k(141) * X(212) - X(45) * X(398); 
dx(399) = k(142) * X(221) - X(49) * X(399); 
dx(400) = k(146) * X(249) - X(72) * X(400); 
dx(401) = k(144) * X(231) - X(57) * X(401); 
dx(402) = k(143) * X(235) - X(61) * X(402); 
dx(403) = k(147) * X(321) - X(122) * X(403); 
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dx(404) = k(33) * X(152) - X(9) * X(404); 
dx(406) = X(405) * Xind(139) + k(150) * X(408) - k(149) * X(406) * X(407); 
dx(407) = k(150) * X(408) - k(149) * X(406) * X(407); 
dx(408) = k(149) * X(407) * X(406) - k(150) * X(408); 
dx(410) = Xind(140) * X(409) + k(153) * X(412) - k(152) * X(410) * X(411); 
dx(411) = k(153) * X(412) - k(152) * X(410) * X(411); 
dx(412) = k(152) * X(410) * X(411) - k(153) * X(412); 
end 
 
Run Document 
options = odeset('NonNegative',1:412); 
% options = odeset('JPattern',S,'Vectorized','on'); 
disp('in run') 
[t,X] = ode15s(@RemyelinationBackupHalfTreat_eq, tspan, X0, options); 
plot(t,X) 
Analysis Document 
 
% Make the species concentrations or rate constants you wish to change 
% global variables. 
global B C D E F G I K W Z Y A1 A2 
  
 B = 0; % Glatiramer Acetate 
 C = 0; % Benztropine 
 D = 0; % Simvastatin 
 E = 0; % Lovastatin 
 F = 0; % Clobetasol 
 G = 0; % Halcinonide 
 I = 0; % Experimental Treatment 
 K = 0; % rHIgM22 
 W = 0; % GNbAC1 
 Y = 0; % FTY720  
 Z = 0; % Indometacin 
 A1 = 0; % LiCl 
 A2 = 0; % BIIB033 
     
  
RemyelinationBackupHealthy_run 
dataHealthy = X; 
  
RemyelinationBackupDisease_run 
dataDisease = X; 
  
RemyelinationBackupHalfTreat_run 
dataTreatment = X; 
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RemyelinationBackupHalfTreatDose2_run 
dataHalfTreatDose2 = X; 
  
% RemyelinationCombinedHalfTreat_run 
% dataCombinedPart = X; 
  
 B = 0; 
 C = 0; 
 D = 0; 
 E = 0; 
 F = 0; 
 G = 0.01; 
 I = 0; 
 K = 0; 
 W = 0; 
 Y = 0; 
 Z = 0; 
 A1 = 0; 
 A2 = 0; 
  
 RemyelinationBackupDisease_run 
 dataFullTreat = X; 
  
 B = 0; 
 C = 0; 
 D = 0; 
 E = 0; 
 F = 0; 
 G = 0.1; 
 I = 0; 
 K = 0; 
 W = 0; 
 Y = 0; 
 Z = 0; 
 A1 = 0; 
 A2 = 0; 
  
 RemyelinationBackupDisease_run 
 dataDose2 = X; 
  
%  B = 0.1; 
%  C = 0; 
%  D = 0; 
%  E = 0; 
%  F = 0; 
%  G = 0; 
%  I = 0; 
%  K = 0.1; 
110 
 
%  W = 0; 
%  Y = 0; 
%  Z = 0; 
%  A1 = 0; 
%  A2 = 0; 
%   
%  RemyelinationBackupDisease_run 
%  dataCombined = X; 
  
  
difference = dataDisease - dataHealthy; 
differencePartTreat = dataTreatment - dataHealthy; 
differenceFullTreat = dataFullTreat - dataHealthy; 
differenceDose2 = dataDose2 - dataHealthy; 
differenceHalfDose2 = dataHalfTreatDose2 - dataHealthy; 
% differenceCombined = dataCombined - dataHealthy; 
% differenceCombinedPart = dataCombinedPart - dataHealthy; 
  
RemyelinationBackup_plots2 
  
  
species = {'X1','X2','X3','X4','X5','X6','X7','X8','X9','X10','X11',... 
    'X12','X13','X14','X15','X16','X17','X18', 'X19', 'X20', 'X21',... 
    'X22', 'X23', 'X24', 'X25', 'X26', 'X27', 'X28', 'X29', 'X30',... 
    'X31', 'X32', 'X33', 'X34', 'X35', 'X36', 'X37', 'X38', 'X39',... 
    'X40', 'X41', 'X42', 'X43', 'X44', 'X45', 'X46', 'X47', 'X48',... 
    'X49', 'X50', 'X51', 'X52', 'X53', 'X54', 'X55', 'X56', 'X57',... 
    'X58', 'X59', 'X60', 'X61', 'X62', 'X63', 'X64', 'X65', 'X66',... 
    'X67', 'X68', 'X69', 'X70', 'X71', 'X72', 'X73', 'X74', 'X75',... 
    'X76', 'X77', 'X78', 'X79', 'X80', 'X81', 'X82', 'X83', 'X84',... 
    'X85', 'X86', 'X87', 'X88', 'X89', 'X90', 'X91', 'X92', 'X93',... 
    'X94', 'X95', 'X96', 'X97', 'X98', 'X99', 'X100', 'X101', 'X102',... 
    'X103', 'X104', 'X105', 'X106', 'X107', 'X108', 'X109', 'X110',... 
    'X111', 'X112', 'X113', 'X114', 'X115', 'X116', 'X117', 'X118',... 
    'X119', 'X120', 'X121', 'X122', 'X123', 'X124', 'X125', 'X126',... 
    'X127', 'X128', 'X129', 'X130', 'X131', 'X132', 'X133', 'X134',... 
    'X135', 'X136', 'X137', 'X138', 'X139', 'X140', 'X141', 'X142',... 
    'X143', 'X144', 'X145', 'X146', 'X147', 'X148', 'X149', 'X150',... 
    'X151', 'X152', 'X153', 'X154', 'X155', 'X156', 'X157', 'X158',... 
    'X159', 'X160', 'X161', 'X162', 'X163', 'X164', 'X165', 'X166',... 
    'X167', 'X168', 'X169', 'X170', 'X171', 'X172', 'X173', 'X174',... 
    'X175', 'X176', 'X177', 'X178', 'X179', 'X180', 'X181', 'X182',... 
    'X183', 'X184', 'X185', 'X186', 'X187', 'X188', 'X189', 'X190',... 
    'X191', 'X192', 'X193', 'X194', 'X195', 'X196', 'X197', 'X198',... 
    'X199', 'X200', 'X201', 'X202', 'X203', 'X204', 'X205', 'X206',... 
    'X207', 'X208', 'X209', 'X210', 'X211', 'X212', 'X213', 'X214',... 
    'X215', 'X216', 'X217', 'X218', 'X219', 'X220', 'X221', 'X222',... 
    'X223', 'X224', 'X225', 'X226', 'X227', 'X228', 'X229', 'X230',... 
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    'X231', 'X232', 'X233', 'X234', 'X235', 'X236', 'X237', 'X238',... 
    'X239', 'X240', 'X241', 'X242', 'X243', 'X244', 'X245', 'X246',... 
    'X247', 'X248', 'X249', 'X250', 'X251', 'X252', 'X253', 'X254',... 
    'X255', 'X256', 'X257', 'X258', 'X259', 'X260', 'X261', 'X262',... 
    'X263', 'X264', 'X265', 'X266', 'X267', 'X268', 'X269', 'X270',... 
    'X271', 'X272', 'X273', 'X274', 'X275', 'X276', 'X277', 'X278',... 
    'X279', 'X280', 'X281', 'X282', 'X283', 'X284', 'X285', 'X286',... 
    'X287', 'X288', 'X289', 'X290', 'X291', 'X292', 'X293', 'X294',... 
    'X295', 'X296', 'X297', 'X298', 'X299', 'X300', 'X301', 'X302',... 
    'X303', 'X304', 'X305', 'X306', 'X307', 'X308', 'X309', 'X310',... 
    'X311', 'X312', 'X313', 'X314', 'X315', 'X316', 'X317', 'X318',... 
    'X319', 'X320', 'X321', 'X322', 'X323', 'X324', 'X325', 'X326',... 
    'X327', 'X328', 'X329', 'X330', 'X331', 'X332', 'X333', 'X334',... 
    'X335', 'X336', 'X337', 'X338', 'X339', 'X340', 'X341', 'X342',... 
    'X343', 'X344', 'X345', 'X346', 'X347', 'X348', 'X349', 'X350',... 
    'X351', 'X352', 'X353', 'X354', 'X355', 'X356', 'X357', 'X358',... 
    'X359', 'X360', 'X361', 'X362', 'X363', 'X364', 'X365', 'X366',... 
    'X367', 'X368', 'X369', 'X370', 'X371', 'X372', 'X373', 'X374',... 
    'X375', 'X376', 'X377', 'X378', 'X379', 'X380', 'X381', 'X382',... 
    'X383', 'X384', 'X385', 'X386', 'X387', 'X388', 'X389', 'X390',... 
    'X391', 'X392', 'X393', 'X394', 'X395', 'X396', 'X397', 'X398',... 
    'X399', 'X400', 'X401', 'X402', 'X403', 'X404', 
'X405','X406','X407','X408','X409','X410','X411','X412'}; 
  
cellDiff = cell(412,1); 
  
% Add the values of the difference, one at a time, into the cell. 
for i = 1:412 
    cellDiff(i) = {difference(:,i)}; 
end 
  
% Create tables with the maximum and minimum values of each species. Change 
% the variable name of the cell (in this case cellDiff) and array length  
% (in this case 18) to fit your model. 
maxDiff = sortrows(stack(varfun(@max,struct2table(cell2struct(cellDiff,... 
    species,1))),1:412,'NewDataVariableName','Relative_Value',... 
    'IndexVariableName','Variable'),2,'descend'); 
minDiff = sortrows(stack(varfun(@min,struct2table(cell2struct(cellDiff,... 
    species,1))),1:412,'NewDataVariableName','Relative_Value',... 
    'IndexVariableName','Variable'),2); 
  
maxDiff(1:10,:) 
minDiff(1:10,:) 
 
Example of Plots Document 
% Create an array the same size as tspan in Example_run. 
t = 0:0.01:120; 
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figure(2) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,325),tspan,differenceFullTreat(:,325),tspan,differencePartTrea
t(:,325),tspan,differenceDose2(:,325),tspan,differenceHalfDose2(:,325),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('MBP - Baseline','MBP Full Treat - Low Dose', 'MBP Part Way Treat - Low 
Dose','MBP Full Treat - High Dose','MBP Part Treat - High 
Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
title('BMPR Antagonist - Effect on MBP Expression','Fontsize',12) 
 
figure(3) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,329),tspan,differenceFullTreat(:,329),tspan,differencePartTrea
t(:,329),tspan,differenceDose2(:,329),tspan,differenceHalfDose2(:,329),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('CNPase - Baseline','CNPase Full Treat - Low Dose', 'CNPase Part Way Treat - 
Low Dose','CNPase Full Treat - High Dose','CNPase Part Treat - High 
Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
title('CNPase','Fontsize',12) 
 
figure(4) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,316),tspan,differenceFullTreat(:,316),tspan,differencePartTrea
t(:,316),tspan,differenceDose2(:,316),tspan,differenceHalfDose2(:,316),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('PLP - Baseline','PLP Full Treat - Low Dose', 'PLP Part Way Treat - Low 
Dose','PLP Full Treat - High Dose','PLP Part Treat - High 
Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
title('PLP','Fontsize',12) 
 
figure(5) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,334),tspan,differenceFullTreat(:,334),tspan,differencePartTrea
t(:,334),tspan,differenceDose2(:,334),tspan,differenceHalfDose2(:,334),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('Remyelination - Baseline','Remyelination Full Treat - Low Dose', 
'Remyelination Part Treat - Low Dose','Remyelination Full Treat - High 
Dose','Remyelination Part Treat - High Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
113 
 
title('SMO Receptor Agonist - Effect on Remyelination','Fontsize',12) 
 
figure(6) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,363),tspan,differenceFullTreat(:,363),tspan,differencePartTrea
t(:,363),tspan,differenceDose2(:,363),tspan,differenceHalfDose2(:,363),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('Beta Catenin - Baseline','Beta Catenin Full Treat - Low Dose', 'Beta Catenin 
Part Way Treat - Low Dose','Beta Catenin Full Treat - High Dose','Beta Catenin Part 
Treat - High Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
title('Lithium Effect on Beta Catenin Levels','Fontsize',12) 
 
figure(7) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,213),tspan,differenceFullTreat(:,213),tspan,differencePartTrea
t(:,213),tspan,differenceDose2(:,213),tspan,differenceHalfDose2(:,213),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('RXRy Complexes - Baseline','RXRy Complexes Full Treat - Low Dose', 'RXRy 
Complexes Part Treat - Low Dose','RXRy Complexes Full Treat - High Dose','RXRy 
Complexes Part Treat - High Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
title('RXRy Complex Formation','Fontsize',12) 
 
figure(8) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,272),tspan,differenceFullTreat(:,272),tspan,differencePartTrea
t(:,272),tspan,differenceDose2(:,272),tspan,differenceHalfDose2(:,272),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('Gernaylgeranyl PP - Baseline','Gernaylgeranyl PP  - Low Dose', 'Gernaylgeranyl 
PP  - Low Dose','Gernaylgeranyl PP  - High Dose','Gernaylgeranyl PP  - High 
Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
title('Geranylgeranyl Pyrophosphate Formation','Fontsize',12) 
 
figure(9) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,181),tspan,differenceFullTreat(:,198),tspan,differencePartTrea
t(:,198),tspan,differenceDose2(:,198),tspan,differenceHalfDose2(:,198),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('OPC Migration - Baseline','OPC Migration Full Treat - Low Dose', 'OPC 
Migration Part Way Treat - Low Dose','OPC Migration Full Treat - High Dose','OPC 
Migration Part Treat - High Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
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ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
title('Anticholinergic Effects on OPC Migration','Fontsize',12) 
 
figure(10) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,160),tspan,differenceFullTreat(:,160),tspan,differencePartTrea
t(:,160),tspan,differenceDose2(:,160),tspan,differenceHalfDose2(:,160),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('OPC Differentiation - Baseline','OPC Differentiation Full Treat - Low Dose', 
'OPC Differentiation Part Way Treat - Low Dose','OPC Differentiation Full Treat - High 
Dose','OPC Differentiation Part Treat - High Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
 
title('OPC Differentiation','Fontsize',12) 
 
figure(11) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,198),tspan,differenceFullTreat(:,181),tspan,differencePartTrea
t(:,181),tspan,differenceDose2(:,181),tspan,differenceHalfDose2(:,181),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('Apoptosis - Baseline','Apoptosis Full Treat - Low Dose','Apoptosis Part Way 
Treat - Low Dose','Apoptosis Full Treat - High Dose','Apoptosis Part Treat - High 
Dose','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
title('TLR2 Antagonist - Effect on Apoptosis','Fontsize',12) 
 
figure(12) 
% Plot specific columns of the matrix. 
plot(tspan,difference(:,334),tspan,differenceFullTreat(:,334),'LineWidth',2) 
% Create a legend in the bottom left corner. 
legend('Remyelination - Baseline','Remyelination - High Dose 
Lithium','Location','SouthWest') 
% Label the axes, set font sizes, and title the plot. 
xlabel('time', 'Fontsize', 8) 
ylabel('relative difference', 'Fontsize', 8) 
set(gca, 'Fontsize', 8) 
title('High Dose Lithium Effect on Remyelination','Fontsize',12) 
 
 

